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Abstract 
 
Robert L. Mango:  Stromal Promotion of Metastasis by Erythroid Differentiation Regulator 1 
(Under the direction of Jonathan S. Serody) 
 
 Stromal cells and the various factors they release play an important role in the 
promotion of tumor growth and metastasis.  The construction of a supportive tumor stroma 
involves the recruitment and activation of multiple cell types.  CC-chemokine receptor 5 
(CCR5) enhances the ability of pulmonary mesenchymal cells (PMCs) to promote metastasis 
of melanoma cells to the lung, by inducing PMC migration and altering gene expression.  In 
a screen of CCR5-depedent gene expression changes during early metastatic colonization, 
Erythroid differentiation regulator 1 (Erdr1) was identified as a potential pro-metastatic 
factor.  While its biochemical mechanism of action has not been fully characterized, Erdr1 
has been shown to act as a survival factor for several types of hematopoietic cells.  The role 
of Erdr1 in stromal promotion of metastasis was investigated, and Erdr1 expression in both 
mouse and human cells was characterized.  The results indicate that Erdr1 is a highly 
conserved gene which is expressed in mouse PMCs upon stimulation of CCR5, and which 
promotes metastasis by enhancing stromal cell survival.  This represents a novel mechanism 
by which chemokine signaling in stromal cells influences the formation of metastasis, and 
establishes Erdr1 as a potentially important regulator of stromal cell processes in both mice 
and humans. 
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Chapter 1 
Background and Significance  
 
 
I. Abstract 
 
 The idea that cell types other than tumor cells play a role in cancer pathogenesis has 
been described by a number of investigators over the past 150 years, but a detailed 
understanding of the complex interactions between tumors and their stroma has only recently 
begun to emerge.  The supportive microenvironment surrounding a tumor is created when 
mesenchymal cells, immune cells, endothelial cells and their precursors are recruited and 
then undergo a phenotypic change to support tumor growth.  Stromal cells also promote 
metastasis, whether from the tumor-adjacent stroma or from the distant target organ.  A 
number of different secreted cytokines and chemokines are involved in this tumor-stroma 
crosstalk, and investigation of gene expression by stromal cells may unveil novel 
pharmacological targets. We have previously found that expression of a chemokine receptor, 
CCR5, by pulmonary mesenchymal cells promoted metastasis to the lung.  Our data 
implicate Erythroid differentiation regulator 1 (Erdr1) in this process.  Erdr1 has been found 
to induce hemoglobin synthesis and to act more generally as a survival factor.  Little has 
been published on this gene, but microarray studies indicate the potential breadth of its 
function.  It is associated with progenitor cells, stromal cells, immune cells, and possibly 
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development.  Our data suggest that the production of Erdr1 by stromal cells is important in 
their ability to promote metastasis and further that Erdr1 may be critical in the survival of 
stromal cells.  This suggests that a better understanding of the mechanisms of Erdr1 action 
and methods to inhibit this protein may have clinical relevance in cancer therapy.  
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II. History of the Concept of Tumor-Stroma Interaction   
 
The analogy of seed and soil. 
In 1889, the British surgeon Stephen Paget wrote of metastasis, “If the remote organs 
in such a case are all alike passive and, so to speak, helpless… then the distribution of cancer 
throughout the body must be a matter of chance.  But if we can trace any sort of rule or 
sequence in the distribution of cancer, … then the remote organs cannot be altogether passive 
or indifferent as regards embolism.”[1]  His survey of 735 breast cancer patient autopsies 
indeed demonstrated statistical correlations between cancer types and their preferred sites of 
metastasis.  To use Paget’s analogy, there might therefore be characteristics of the “soil” 
which are differentially beneficial or detrimental for successful colonization by metastatic 
“seeds.”  Identification and therapeutic manipulation of these characteristics could advance 
the treatment of malignancy. 
 In the years since Paget’s “Seed and Soil Hypothesis,” many soluble factors released 
by different non-tumor cell types have been found to influence metastasis, providing an 
increasingly detailed understanding of the “soil.”  These findings are not limited to sites of 
secondary growth; the tissue surrounding the primary tumor is clearly involved in 
tumorigenesis and metastasis as well.  A complete picture of cancer pathogenesis must 
include the complex microenvironment of reciprocal interactions between genetically 
transformed cells and the multiple other cell populations they encounter. 
 Stroma is a Greek word meaning “bed,” and is used to denote the supportive 
connective tissue of an organ.  Normal tissue stroma consists of mesenchymal cells, 
specifically quiescent fibroblasts, the extracellular matrix (ECM) they produce, small blood 
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vessels, and various types of immune cells.  In the “tumor stroma” immediately surrounding 
tumors all of the above components are present, but in a modified state. 
 
Tumor stroma and normal stroma have differential effects on tumor cells 
 In a 1953 description of 4 clinical cases of skin carcinoma with varying histologies, 
Pinkus noticed that they differed in their position relative to the dermal stroma.  He 
hypothesized that this reflected different direct effects on the tumor by the stroma.[2]  His 
hypothesis was strengthened by van Scott and Reinertson, who elegantly demonstrated that 
stroma was required for maintenance of epidermal cell type, by autologous transplantation of 
epithelial cells to distant areas of the skin or mucosa with or without stroma.  They asked, 
“Since the structure of epithelium seems to be so governed by the supporting stroma, may not 
the different histomorphologic types of basal cell tumors reflect the influence of a particular 
stroma, rather than indicate that the tumor originated from any particular epithelial tissue 
such as hair roots or epidermis?”[3]   
Evidence for direct tumor support by the stroma was provided by Cooper and Pinkus 
in 1977, when they reported that rat basal cell carcinomas transplanted into normal uterine 
walls of congenic rats gradually acquired normal epidermal histology.[4]  Similarly, it was 
found in 1990 that Dunning prostatic adenocarcinoma cells exhibited glandular 
differentiation when implanted with mesenchymal cells from developing male urogenital 
tracts.[5]  Furthermore, normal breast fibroblasts, but not tumor-associated breast fibroblasts, 
were found to inhibit proliferation of a human breast carcinoma line.[6]  By demonstrating 
that normal stromal cells could limit or reverse tumorigenesis, these studies highlighted the 
dependence of tumors on a supportive stroma. 
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Supportive stroma associated with breast cancer biopsies was first described by Bano 
et al. as cells adherent in culture that stimulated the attachment and proliferation of 
carcinoma cells.[7]  Using a similar approach, Gerald Cunha and colleagues extended these 
findings in 1999, showing that cancer-associated fibroblasts (CAFs) isolated from human 
prostate carcinoma biopsies increased the proliferation of transformed prostate epithelial 
cells, reduced apoptosis, and promoted tumorgenesis.  Normal prostate fibroblasts did not 
have this effect, nor did CAFs have this effect on normal prostate epithelium.[8]   
Some types of stromal cells not isolated from tumors were also found to nevertheless 
support pathogenesis.  Picard et al. reported that cultured embryonic fibroblasts promoted the 
growth of subcutaneous implanted tumors, pointing out that these cells might be quite 
different than normal organ-resident fibroblasts.[9]  Noting that tumor stroma often 
histologically resemble the granulation tissue found in wounds, Dvorak described tumors as 
“wounds that do not heal,” proposing that the processes underlying wound healing are also 
supportive for tumors.[10]  Directly testing this hypothesis, Dingemans et al. found that rat 
colon adenocarcinoma implanted in pre-induced skin wounds acquired a more de-
differentiated and invasive morphology than those implanted in normal skin.[11]   
Together these studies established the importance of the stroma on the progression of 
neoplastic disease.  Simultaneous with this work, and with more frequency in the last two 
decades, the various specific roles of the tumor stroma have been elucidated.  These roles 
include: angiogenesis, provision of survival and growth factors, immune modulation, and 
promotion of metastasis.  Tumors themselves have been found to induce such stromal 
changes, which can be thought of as integral to the process of tumor development. 
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III. Construction of Tumor Stroma by Cell Recruitment and Activation 
 
Mesenchymal cells are recruited to tumor stroma. 
 Myofibroblasts are activated fibroblasts that are defined by their expression -smooth 
muscle actin (-SMA).  They also express fibroblast activated protein (FAP), cytokines and 
chemokines, ECM modification proteins, and contractile fibers.  They were first described 
histologically by Gabbiani et al. in wound tissue[12] but they are also apparent in fibrotic 
lesions as well as tumor stroma. [13, 14]  When myofibroblasts are isolated from tumors they 
are often referred to as cancer-associated fibroblasts (CAFs) or tumor-associated fibroblasts 
(TAFs), though it should be noted that various groups use these terms whether or not the 
expression of -SMA was verified.   
 The sources of myofibroblasts in wound tissue and tumor stroma have long been 
hypothesized and debated, but it now seems clear that multiple sources are possible.  
Fibroblasts can migrate into wound tissue from the surrounding normal tissue[15].  Nearby 
epithelial cells may be transformed into fibroblasts, in a process known as epithelial to 
mesenchymal transition (EMT).[16-18]  CAFs can also be derived from tissue resident 
endothelial cells.[19]   
 There is also recent evidence that tissue myofibroblasts can be derived from bone 
marrow cells.  The hematopoietic origin of cells can be tested by generating bone marrow 
chimeric mice in which bone marrow from donor mice expressing a certain marker is 
transplanted into irradiated recipient mice lacking that marker.  Over six to eight weeks, bone 
marrow-derived cells will convert from recipient to donor origin, indicated by their 
possession of the marker used.  This has been demonstrated for myofibroblasts surrounding 
pancreatic tumors[20, 21], in Lewis lung carcinoma (LLC) stroma[22], in graft vs. host 
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disease mediated intestinal inflammation[23], in pulmonary fibrosis[24], in liver fibrosis[25], 
and in cutaneous wound healing[26, 27].  Furthermore, the percentage of cells in the stroma 
of pancreatic tumors that were bone marrow-derived correlated strongly with the size of the 
stroma.[28]  
 Experimental evidence largely indicates that fibrocytes, as well as hematopoietic stem 
cells and mesenchymal stem cells, are the circulating myofibroblast precursors that migrate 
into reactive stroma.  The initial description of fibrocytes and their role in wound healing was 
reported by Bucala et al.[29].  They described circulating cells expressing CD45, CD34, 
vimentin, and collagen I, which were recruited to wound sites where they differentiated into 
myofibroblasts and contributed to fibrotic scar formation.[29]  Mori et al. later demonstrated 
that fibrocytes recruited to wound sites gradually acquired expression of -SMA.[30]   
CD14
+
 monocytes can differentiate into fibrocytes in vitro given T cell contact, and 
then differentiate further into myofibroblasts, both of which processes are enhanced by 
transforming growth factor  (TGF-.[31, 32]  The T helper cell type 2 (Th2) polarizing 
cytokines IL-4 and IL-13, previously found to be associated with lung fibrosis, induce 
differentiation of monocytes into fibrocytes in vitro, while the T helper cell type 1 (Th1) 
cytokines IL-12 and IFN- inhibit it.[33]   
Recently Darrel Pilling and colleagues have defined human fibrocytes as CD45RO
+
, 
25F9
+
, S100A8/9
+
, and PM-2K-, by testing a panel of markers and validating cell type by a 
combination of in vitro differentiation and microscopic examination. The expression of 25F9 
distinguishes them from their monocyte precursors, and lack of PM-2K distinguishes them 
from macrophages.  According to Pilling et al., after differentiation of fibrocytes into 
fibroblasts, CD45RO and S100A8/9 expression is lost, and CD90 (Thy1), fibronectin, 
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hyaluronan, and TE-7 are expressed,[34] though other studies have shown that only a portion 
of the fibroblast population expresses Thy1.   
If fibrocytes are derived from monocytes in vitro, this would imply that some 
fibroblasts in vivo ultimately arise from hematopoietic stem cells (HSCs).  Indeed, HSCs 
gave rise to fibroblasts in an ex vivo model[35], and to tumor-infiltrating fibrocytes in 
vivo.[36]  Mesenchymal stem cells (MSCs), however, have also been proposed as sources for 
tumor stromal fibroblasts.[37-39]  These cells are often thought of as residing in the bone 
marrow and occasionally circulating in the periphery, but it should be noted that they are 
theoretically present in any mesenchymal tissue, and so they do not necessarily originate in 
the bone marrow.   
It has been recently questioned whether MSCs represent a distinct cell type from 
fibroblasts.[40]  In fact, MSCs and fibrocytes have many similarities as well, except that 
MSCs lack the hematopoietic markers CD45 and CD34.   It should also be noted that all 
stromal cells in tissues vary in their expression of -SMA, vimentin, collagen I, and S100A4, 
with different populations overlapping in expression of one or more of the markers, 
indicating that they are heterogeneous and possibly dynamic.[41, 42]   
Fibrocytes have been shown to contribute to myofibroblast-mediated pathologies 
other than cancer, including lung fibrosis[43-48], dermal fibrosis[30, 49], asthma[50-52], and 
ischemic cardiac myopathy[53].  Migration of fibrocytes into these lesions is mediated by the 
inflammatory chemokines CCL2[30] and CCL3[45], the homeostatic chemokines 
CCL21[31] and CXCL12[44], and other factors such as insulin-like growth factor binding 
protein-5 (IGFBP-5)[48], and adenosine[49]. 
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Activated fibroblasts promote tumor growth 
When fibrocytes enter the stroma in any of these processes, they differentiate into 
fibroblasts and then are activated to become myofibroblasts.  Activation of fibroblasts, 
signified by induction of -SMA, and their subsequent promotion of tumor growth can be 
achieved through stimulation by TGF-[54-57], IL-4 and IL-13[58], signaling through 
TLR2, TLR4, and TLR7[59], and possibly through excessive cell contact.[60]   The ability of 
activated fibroblasts to support tumor growth is further enhanced by stimulation of platelet-
derived growth factor (PDGF) receptors[61-66].  It has also been found that factors released 
by tumor cells can induce MSCs to differentiate into myofibroblasts,.[39, 67]   
The fibroblast-derived factors mediating tumor growth have been partially defined.  
In an early co-culture experiment, Valverius et al. found that breast fibroblasts supported 
anchorage independent growth of transformed breast epithelial cells, through secretion of 
transforming growth factor  (TGF) and fibroblast growth factor 2 (FGF-2).[68]  Other 
groups have found that co-injection of tumor cells with fibroblasts enhanced tumor 
growth.[69-71]  Other factors include matrix metalloproteases (MMPs)[72-74], which 
degrade the ECM, hepatocyte growth factor (HGF)[75-79], TGF[79], FGF-2[56, 80], 
CXCL12[81-84], connective tissue growth factor (CTGF)[57], IL-6[38, 85, 86], S100A4[87], 
and osteopontin[64].  Through release of these factors, recruited and activated fibroblasts 
directly promote tumor growth.  
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Immune escape involves recruitment and suppression of immune cells.  
Rudolf Virchow hypothesized in 1863 that tumors themselves were caused by chronic 
inflammation after observing the frequent co-localization of tumors and inflammatory 
cells.[88]  As mentioned previously, the resemblance of tumor stroma to granulation tissue 
prompted Dvorak to refer to tumors as “wounds that do not heal.” [10]  Both Dvorak and 
Virchow partly based these views on histological evidence of immune cell infiltration of 
tumor stroma.  Certainly some immune cells infiltrating tumors have anti-tumor functions, 
particularly CD8
+
 cytotoxic T lymphocytes (CTL) and natural killer (NK) cells.  It is widely 
hypothesized that many subclinical neoplasms are cleared by the immune system before they 
can cause significant disease (for a recent introductory review on anti-tumor immunity, see 
[89]).  However, the accumulation of suppressed immune cells often counteracts tumor 
rejection, leading to the need for therapeutic intervention.   
In 1983, Montovani and colleagues demonstrated that tumor conditioned media 
induced chemotaxis of macrophages, and the number of tumor-associated macrophages 
(TAMs) in the tumor stroma in vivo correlated with the ability of a given tumor cell line to 
condition media for macrophage chemotaxis in vitro.[90]  In 1985 Taylor and Black reported 
that B16-F10 melanoma-derived membrane microvessicles inhibited the activation of 
macrophages.[91]  TAMs have a suppressive “Type 2” macrophage (M2) phenotype, 
characterized by secretion of IL-10, IL-1R antagonist, and chemokines for Th2 cells and 
regulatory T cells (Treg).[92]  TAMs have been found to secrete TGF-1, resulting in 
suppression of activated T cell proliferation[93] and to promote the expression of pro-
myofibroblast and pro-angiogenesis cytokines by tumor cells.[94] 
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Another immune cell found in tumor stroma is the myeloid-derived suppressor cell 
(MDSC).  These are immature myeloid cells of either monocytic or granulocytic lineages, 
and are dramatically expanded in the spleens and peripheral blood of tumor-bearing 
animals[95, 96] and patients[97, 98].  Treg are also found in the tumor stroma and contribute 
to immune suppression.  Among other functions, they have been found to contribute to the 
suppressive phenotype of TAMs.[99]  Treg also partially mediate the suppressive effect of 
MDSCs.[100]  Reciprocally, MDSCs inhibit CD4
+
 and CD8
+
 effector T cell function.[101]   
Fibroblasts in the tumor stroma recruit and influence the suppressed phenotype of 
these cell types.  S100A9, often expressed by tumor stroma, contributes to the accumulation 
of MDSCs in tumor-bearing mice, as well as the reduction of dendritic cells.[102]  Stroma-
derived TGF1, has many immune suppressive effects, including the polarization of adaptive 
Treg[103], recruitment of TAMs [104], recruitment of MDSCs[105], and possibly polarization 
of suppressive neutrophils[106].  Stroma-derived CCL2 recruits monocytes[107] and T 
cells[108], and enhances to pro-tumor activity of TAMs[109, 110].  Tumors have been found 
to induce fibroblasts to express the chemokines CXCL1, 2, and 5, and CCL3, as well as the 
cytokines IL-11 and IL-1.[111, 112] 
Fibroblasts also inhibit T cell activation[113, 114] and antigen presenting cell (APC) 
activity, particularly through the expression of indolamine 2-3 dioxygenase (IDO).[115, 116]  
Activated fibroblasts have been shown to induce FasL-mediated death of T cells.[117]  
MSCs, which are phenotypically similar to fibroblasts, also inhibit T cell activation[118], 
possibly through IGF binding proteins[119] or IDO[120].  Moreover, proliferation of 
previously activated T and B cells can be inhibited by MSCs[121], as can dendritic cell 
activation[122-124].  Immunosuppression mediated by mesesnchymal cells is relevant to 
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tumor immunity, since injection of MSCs allowed growth of B16-F10 melanoma cells in 
allogeneic mice.[125, 126]     
 
Fibroblasts and recruited monocytes contribute to angiogenesis.  
The formation of new blood vessels to support tumor growth is another important 
function of the stroma.  In 1971, Folkman and colleagues, hypothesized that angiogenesis 
was crucial for tumor growth, and proposed targeting this process as a tumor treatment 
strategy.[127]   As with other stromal processes, angiogenesis involves the recruitment of 
multiple cell types.  After transplant with green fluorescent protein (GFP) expressing HSCs, 
GFP positive endothelial cells were found in the stroma of Lewis Lung tumors.[22]  Other 
studies have shown that both monocytes[128] and mesenchymal cells[128, 129] are recruited 
to the vascular regions of tumor stroma.  Circulating endothelial cells are also recruited[83, 
130] and this may in part be mediated by fibroblast-derived  CXCL12[83].  The recruitment 
of  bone marrow-derived fibroblasts and bone marrow-derived endothelial cells appears to be 
important, since a survey of 10 different tumor types found that it is correlated with tumor 
growth rate.[131] 
Vascular endothelial growth factor (VEGF) was first identified by Dvorak and 
colleagues in ascites fluid from tumor-bearing guinea pigs, and in multiple tumors and tumor 
lines.[132]  Six years later, two separate groups found that it promoted endothelial cell 
proliferation[133, 134], and also induced monocyte activation and migration[135].  Today 
VEGF is recognized as a major contributor to tumor angiogenesis, and blockade of VEGF in 
cancer patients has been shown to prolong survival when combined with chemotherapy (for a 
recent review, see [136]).  Of particular interest here is the work by Lyden et al., showing 
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that tumor angiogenesis depends on VEGFR-mediated recruitment of bone marrow-derived 
hematopoietic and endothelial cell precursors.[137]  TAFs have been shown to express 
VEGF, particularly the Thy1
+
 population.[86]   
Other fibroblast-produced cytokines previously discussed promote angiogenesis as 
well, including TGF-[138], IL-1 and IL-1[139], and CXCL12 [140].  In EL4 tumors, 
which do not respond to anti-VEGF antibody therapy, TAFs were found to express high 
levels of PDGF-C, a gene closely related to VEGF.  When PDGF-C was blocked, 
angiogenesis and tumor growth was reduced.[141] 
 
 
 Taken together, these studies show that the construction of the tumor 
microenvironment depends on the recruitment of multiple cell types, which are then 
stimulated by tumor cells to secrete tumor-supporting factors.  While immune cells and 
vascular endothelial precursors are vital for tumor protection and blood supply, the 
expression of chemokines and growth factors relevant to all of these processes establishes 
mesenchymal cells as a central player in tumor growth. 
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IV. Mesenchymal Cells and Metastasis 
 
Activated fibroblasts at the primary tumor site promote metastasis 
 In 1987, Stoker et al. reported that a fibroblast-derived protein induced scattering of 
epithelial cells in vitro, and named the protein scatter factor.[142]  They later found that it 
induced the invasion of human carcinoma lines in vitro, and that it was identical to the 
previously discovered protein HGF.[143, 144]  They hypothesized that in vivo, HGF might 
enhance the metastatic potential of tumor cells.    
Indeed, HGF was found to be expressed in many human malignant tumors [75], and 
in vivo animal models showed that their hypothesis was correct.[145, 146].  The evidence for 
expression of HGF by tumor stromal cells has been discussed above, but it is of note that 
three different tumor lines induced HGF production by fibroblasts in co-culture, and this in 
turn promoted the invasiveness of the tumor cells.[76]   
 Other molecules secreted by stroma have been found to promote the progression of 
tumors to a metastatic phenotype, including MMP-9[147], monocyte colony stimulating 
factor (M-CSF)[148], and TGF-1[105].  In a reciprocal enhancement of motility, tumor-
derived microvessicles induced fibroblast migration, and fibroblasts exposed to tumor 
microvessicles induced migration of PC3 cancer cells in culture.[149] 
Chemokines are known to induce chemotaxis, but they can also directly enhance the 
metastatic potential of tumors.  MSCs increased the metastatic potential of four separate 
breast cancer lines in vivo, and this was found to depend on MSC expression of CCL5 
(RANTES) and tumor cell expression of CCR5.[150]   Furthermore, CXCL12 and CCL21 
increase the metastatic potential of tumor cells by preventing anoikis, the process of cell 
death stimulated by lack of ECM contact.[151] 
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Chemokines direct metastatic cells to secondary sites 
Human breast cancer cells were found to express CXCR4 and CCR7, the expression 
of whose ligands,  CXCL12 and CCL21, were found to be higher in the tissues to which 
breast cancer metastasizes.  Human melanoma cells, which have similar metastatic target 
organs, also expressed these two receptors, in addition to CCR10, whose ligand CCL27 is 
expressed in skin.  Antibody neutralization of CXCR4 in SCID mice injected with human 
breast cancer cells reduced metastasis to the lungs and lymph nodes.[152]  B16-F10 
melanoma cells were found to migrate towards fibroblast-derived proteins S100A8 and 
S100A9 via the RAGE receptor.[153] 
CXCR4 was also expressed by multiple patient samples and cell lines of pancreatic 
tumors, and expression correlated with metastasis.[154]  Forced over-expression of CXCR4 
in B16-F10 cells increased metastasis to the lung and skin.[155] CXCR4 expression is 
upregulated by hypoxia in tumor cells[154] and many normal cell types[156], suggesting a 
process in which cells in the middle of a tumor that has outgrown its blood supply might 
prepare for metastasis.  Forced expression of CCR7 was shown by Wiley et al. in 2001 to 
drive melanoma metastasis to lymph nodes, which express CCL21.[157]  It was recently 
shown that T cell acute lymphocytic leukemia brain metastasis also depends on migration via 
CCR7.[158]   
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Mesenchymal cell gene expression determines the “fertility” of the “soil” 
 Regardless of whether the construction of supportive stroma in distant organs must 
occur prior to colonization, there is evidence that the stromal gene expression does influence 
metastasis.  Many of the stroma-derived factors that support primary tumor growth also 
support the development of metastases in experimental models, including HGF[159], IL-
6[85], and MMP-9[160].  Some of these factors, or genes regulating them, appear to be 
particularly important for stromal promotion of metastasis. 
For example, S100A4, expressed by activated fibroblasts[161], has long been 
appreciated as a tumor cell-expressed gene promoting metastasis through induction of 
MMPs.[162-165]  However, it has more recently been demonstrated that S100A4 expressed 
by other cells can also promote metastasis.[166, 167]  In fact, S100A4 deficient mice were 
found to be completely resistant to breast cancer metastasis to the lung, and this was reversed 
by transfer of WT fibroblasts.[87]  Saha et al. recently provided evidence that S100A4 and 
S100A8 were negatively regulated by utereoglobin (UG).  UG knockout mice expressed 
more of these genes in lung tissue than WT mice, and developed more metastases.[153] 
Conversely, a tumor cell-derived proteoglycan, versican, stimulated monocytes 
through TLR2 to produce IL-6 and TNF, and this promoted metastasis.[168]  Metastasis of 
colon cancer was found to be dependent on stromal expression of PDGFR.[65, 85, 87, 153] 
CXCL12 and TNF-related apoptosis inducing ligand (TRAIL) expression in the bone 
marrow has been found to support survival of breast cancer metastases to the bone 
marrow.[169]  These examples illustrate that target organ gene expression directly effects the 
process of metastasis. 
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In 2005 our group reported that CCR5
-/-
 mice develop fewer metastases than wild 
type (WT) mice.[170]  This was determined not to be dependent on expression of CCR5 on 
hematopoietic cells, as reconstitution of irradiated CCR5
-/- 
mice with WT bone marrow did 
not result in increased metastasis formation.  Rather, transfer of WT pulmonary 
mesenchymal cells (PMCs) to CCR5
-/-
 mice prior to tumor cell injection resulted in numbers 
of metastases similar to WT mice, indicating that expression of CCR5 increased the ability of 
PMCs to support metastasis.[170] 
Further work demonstrated that fibrocytes expressed CCR5, and migrated into the 
lungs more efficiently than CCR5
-/-
 fibrocytes after transfer.  Once in the lung, WT 
fibrocytes increased expression of MMP-9, which was found in vitro to be stimulated by the 
CCR5 ligand CCL5.  Multiple other chemokines were also demonstrated to be expressed in 
resting lungs, indicating that fibrocytes could migrate into lungs in a chemokine specific 
manner under normal conditions, i.e. before metastatic colonization.  In fact, 15-20% of 
resting lung PMCs cultured ex vivo were found to be CD45
+
 fibrocytes, which partly 
explained how these bone marrow-derived cells could promote metastasis in the previous 
study even after irradiation.[171]   
 The results of these studies were confirmed and extended by Wu et al., who also 
found reduced metastases in CCR5
-/-
 mice, as well as mice deficient in the CCR5 ligand 
CCL3.  In addition, they found increased migration of monocytes and fibroblasts into the 
lungs of WT mice after tumor injection, as well as increased monocyte-derived MMP-9 and 
fibroblast-derived HGF expression, relative to CCR5
-/-
 or CCL3
-/-
 mice.[159] 
 Previous work had demonstrated a delay in tumor growth in CCR5 
-/-
 mice, and these 
mice responded better to therapeutic vaccine with WT dendritic cells than did WT mice, but 
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the effect on primary tumor growth without vaccine was not statistically significant.[172]  
However, the significant effect of CCR5 on metastasis development suggests that the 
construction of supportive stroma in the secondary organ may depend more on CCR5 
signaling than that of primary tumor stroma.  The role of CCR5 in metastasis and tumor 
vaccine response is particularly clinically relevant, since an effective CCR5 inhibitor, 
Maraviroc, is available and approved for use in preventing human immunodeficiency virus 
(HIV) infection of T cells.[173] 
 CCR5 
-/-
 mice were defective in the ability of their PMCs to contribute to pro-
metastatic stroma, but the mechanism of this defect was not initially clear.  Therefore, a 
comparative gene expression study was undertaken in WT vs. CCR5
-/-
 lungs soon after 
injection of malignant melanoma cells, as will be discussed in Chapter 2.  One potential pro-
metastatic candidate identified was a little-studied gene with no previous connection to 
metastasis: erythroid differentiation regulator 1 (Erdr1). 
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V. Background on Erythroid Differentiation Regulator 1  
 
Initial Characterization of Erdr1 
In 1992 Dormer and colleagues presented data at the annual meeting of the Society 
for Hematology and Stem Cells showing that media conditioned by the myelomonocytic 
leukemia cell line WEHI-3B induced differentiation of an erythoblastic leukemia cell 
line.[174]  As described in a pair of articles in 2004, the responsible factor was isolated and 
called Erythroid Differentiation Regulator 1 (Erdr1, previously Edr1).[175, 176]   
The differentiation of cells in the erythroid lineage results in increased expression of 
hemoglobin, which can be measured using a benzidine-based colorimetric assay.  Dormer et 
al. used this assay to screen a WEHI-3B cDNA library for clones expressing the hemoglobin-
inducing factor.  The insert sequence of the single positive clone had an open reading frame 
of 534 bp (177 amino acids), had no homology to other known genes, and was named Erdr1.  
Both recombinant Erdr1 and WEHI-conditioned media were found to induce hemoglobin 
synthesis over a biphasic dose-response curve.  Erdr1 protein was detected in primary murine 
lymphoma, a murine lymphoblastoid cell line, human G-CSF mobilized CD34
+
 stem cells, 
PBMCs from chronic myelogenous leukemia (CML) and B cell chronic lymphocytic 
leukemia (CLL) patients, and human umbilical cord blood T cells.  Immunofluorescense 
staining of murine erythroleukemia cells and human cord blood T cells revealed that Erdr1 
was localized to the cell membrane and appeared to be released in membrane vesicles, 
though its hemoglobin inducing activity was demonstrated in both the vesicle and soluble 
fractions of conditioned media.[175] 
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In a second round of screening of the WEHI-3B cDNA library using the clone from 
the first screen, a transcript with a slightly longer ORF (630 bp, 209 aa) was identified.  
Multiple mRNA species were identified by Northern blot, none of which contained either 
fully spliced ORF.  Remarkably, the mRNA sequence with the longer ORF was reported to 
be identical between human and mouse, when amplified by RT-PCR.[175]  The details of the 
molecular characterization of Erdr1 will be further discussed in Chapter 3. 
Dormer and colleagues subsequently tested the effects of Erdr1 on human 
hematopoietic progenitors and a Burkitt’s lymphoma cell line (BL-70).  When BL-70 cells 
are removed from their stromal cell feeder layer, they undergo apoptosis unless they are 
cultured at very high cell densities.  Erdr1 protected BL-70 from apoptosis at low cell density 
and reduced the cell density necessary for survival.  However, this was only true at certain 
concentrations, and Erdr1 enhanced apoptosis at higher concentrations.  Regarding 
hematopoietic progenitors, such biphasic responses were also seen in erythroblast 
differentiation and proliferation of primary human erythroid and granulocytic/monocytic 
progenitors.[176] 
A recurring theme in the initial studies of Erdr1 is the association with stress 
responses.  WEHI-3B cells expressed and released more Erdr1 after incubation in serum-free 
media.[175]  NIH 3T3 (murine embryonic fibroblasts) released Erdr1 after switching from 
10% to 2% serum-supplemented media[175], and after trypsinization[176].  MEL cells 
released Erdr1 upon transfer to PBS, incubation at room temperature, incubation at 41.5 C, 
and exposure to H2O2.[176]  .   
Together, these findings suggest that Erdr1 is a widely expressed, highly conserved 
cell stress-related cytokine that can act as both a survival factor and as an inducer of 
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differentiation.  Dormer et al. have hypothesized from its expression in multiple organs and 
cell types that its function is likely more general than related to the expression of hemoglobin 
during hematopoiesis.  Indeed, the bioinformatics data now available through BioGPS[177] 
confirms expression in a wide range of tissues and cells, the highest being the female 
reproductive organs, the spleen, the CNS, and embryonic stem cells (see Appendix I).  
Further insight into the broad range of the potential roles Erdr1 might play can be attained 
through a survey of functional genomics databases (see Appendix II).  While these data are 
by their nature preliminary, in the absence of conserved domains or sequence homology to 
other genes, they provide a valuable framework for the interpretation of studies directly 
targeting Erdr1. 
 
Erdr1 in Stem Cells and Progenitors 
 Since Erdr1 was first isolated from myelomonocytic leukemia cells (WEHI-3B) and 
its effects studied in hematopoietic progenitors, it is not surprising that multiple groups have 
found its expression to be associated with cells that are less differentiated (App. II, 1-9).  
Sung et al. found it to be 4 to10 -fold higher in hematopoietic stem cells and progenitors than 
in granulocytes[178] (App. II, 2-4) and Liadaki et al. found it more than 3 -fold higher in 
bone marrow side population cells identified by Hoechst 33342 stain[179] (App. II, 6).  
Silva-Vargas et al. found that induction of -catenin conditional transgenic mice on the skin, 
which induces de-differentiation of hair follicles, also induced a roughly 13 -fold increase in 
Erdr1.[180] (App. II, 1)  Conversely, differentiation of C2C12 myoblasts to myotubes was 
associated with a roughly 2 -fold decrease in Erdr1 expression.[181, 182] (App. II, 8-9)      
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The association of Erdr1 expression with less differentiated hematopoietic cells in 
expression arrays (App. II, #2-4, 6) led Denault et al. to include it in a functional in vivo 
screen of potential promoters of HSC self-renewal.  104 candidate genes were transduced 
into HSCs, which were then tested in an in vivo competitive re-population assay.  Erdr1 
increased HSC activity by about 4-fold, decreased HSC apoptosis, and increased HSC 
expansion in vitro.  Erdr1-transduced HSCs isolated from mice in the primary re-population 
assay were also found to promote secondary re-population in a new group of mice, indicating 
that its mechanism of action was increasing HSC self-renewal rather than increasing the 
efficiency of differentiation to pluripotent cells.[183] 
Their purpose for doing the screen was to identify a small set of genes which, when 
transfected together into a terminally differentiated hematopoietic cell, would return it to a 
HSC phenotype.  While several arrays associate Erdr1 with less differentiated cells, there has 
been no evidence to date that Erdr1 can reverse the differentiation of cells, and a simple HSC 
pro-survival effect cannot be ruled out as an explanation for their results.     
 
Erdr1 in Stromal Cells 
 Dormer et al. found that the human bone marrow stromal cell line L88/5 released a 
factor when irradiated that induced MEL hemoglobin synthesis, though they did not 
definitively demonstrate that this factor was Erdr1.[175]  They further showed that 
recombinant Erdr1 partially substituted for a stromal cell feeder layer in the culture of 
Burkitt’s lymphoma cells.[176]  Microarray cDNA analyses too have associated Erdr1 with 
stroma.  Stimulation of MEFs with FGF-2 induced expression of Erdr1. (unpublished study, 
GEO dataset GDS2421) (App II, 23)  Furthermore, the stromavascular fraction of adipose 
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tissue was found to express 4 to 5 -fold more Erdr1 than the adipocyte fraction.[184] (App II, 
17-18) 
  
In conclusion, the hypotheses of Paget in 1889 and Pinkus in 1953 that stroma plays 
an active role in cancer progression have been validated both generally and specifically 
regarding certain stromal cell types and factors.  The construction of tumor stroma includes 
the recruitment and activation of mesenchymal cells, both tissue-resident and bone marrow-
derived.  Tumor stroma construction also involves recruitment of endothelial cell precursors 
for angiogenesis and of immune cells, both of which also interact with tumors and 
mesenchymal cells to promote tumor growth and immune escape.   
Cells in the stroma promote the progression of tumors to a metastatic phenotype, and 
once the tumor cells metastasize, cells in distant organ stroma provide a fertile “soil” by 
attracting them via the production of chemokines, modifying the ECM with MMPs, and 
supporting their survival and growth in ways similar to primary stroma.  The recruitment of 
stromal cells to the lungs via CCR5 appears to be important for metastasis.  Data presented in 
Chapter 2 will link Erdr1 to this process as well.  This gene was isolated for its ability to 
induce hemoglobin synthesis in erythroblasts, but its expression by stromal cells under 
stressful conditions and its proven role as a survival factor make it an ideal candidate for 
contributing to the fertility of Paget’s “soil.” 
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I. Summary  
 
We have previously shown that pulmonary mesenchymal cells (PMCs) from CC-
chemokine receptor 5 (CCR5) deficient mice have a reduced ability to promote the 
metastasis of B16-F10 melanoma cells.  To determine the mechanism for this finding we 
used cDNA microarrays to compare the gene expression in wild type (WT) and CCR5 
-/-
 
lungs after intravenous injection of B16-F10 cells.  We found increased expression of Erdr1 
in the lungs of WT compared to CCR5 
-/-
 mice in the first 48 hours after injection of tumor 
cells.  This increase was confirmed by RT-PCR.  Furthermore, WT PMCs expressed more 
Erdr1 than CCR5
-/-
 PMCs in vitro, and stimulation of PMCs with the CCR5 ligand, CCL4, 
increased expression of Erdr1.  Knockdown of Erdr1 in murine embryonic fibroblasts led to a 
reduced ability of those cells to promote B16-F10 metastasis in CCR5
-/-
 but not WT mice.  In 
vitro, Erdr1 knockdown PMCs had a growth disadvantage compared to PMCs expressing 
control shRNA, due to increased apoptosis, which was partially reversed by caspase 
inhibition.  Taken together, our data suggest that CCR5 promotes metastasis by supporting 
PMC survival through induction of Erdr1. 
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II. Significance 
 
Multiple lines of evidence indicate that stromal cells support the formation of 
metastasis through the release of extracellular factors.  Identification of these factors could 
reveal novel targets for therapeutic prevention of malignancy.  Here, we show that the 
stimulation of pulmonary mesenchymal cells (PMCs) through CCR5 leads to the expression 
of a recently characterized gene, Erythroid Differentiation Regulator 1 (Erdr1).  Furthermore, 
Erdr1 acts as a stromal cell survival factor which may be critical for the stromal cell 
promotion of metastases in the lung.  This report is the first to link Erdr1 with metastasis, and 
presents a novel mechanism by which chemokine signaling in stromal cells promotes 
metastasis. 
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III. Introduction 
 
Over the past ten years, evidence has emerged highlighting the importance of  stromal 
cells in cancer progression.  Cells in the tumor stroma promote tumor growth[185], mediate 
angiogenesis[185], contribute to an immune-suppressive microenvironment[89], and increase 
the invasiveness of solid tumors[186].  When tumor cells metastasize, a new supportive 
stroma is constructed around the metastatic nodule.  This requires the secretion of pro-
metastatic factors including MMP-9[160], S100A4[87, 153, 167], S100A8[153], and IL-
6[85].  The activation and proliferation of stromal fibroblasts and the recruitment of 
fibrocytes and other bone marrow-derived cells contribute to the formation of the new 
stroma.  For example, platelet-derived growth factor C (PDGF-C) has recently been shown to 
induce fibroblast activation and recruitment [64], and blockade of its receptor, PDGFR, on 
fibroblasts reduced metastasis in a model of colon cancer[65].   
We have previously shown that mice deficient for CC chemokine receptor 5 (CCR5) 
developed fewer metastases than wild type (WT) mice, and this was reversed by intravenous 
transfer of WT pulmonary mesenchymal cells (PMCs) to CCR5
-/-
 mice.[170]  We 
subsequently showed that CCR5 enhanced the ability of injected PMCs to migrate into the 
lung, but that their persistence there was limited.[171]  Furthermore, stimulation of CCR5 
induced production of MMP-9 by CD45
+
 fibrocytes, which comprised 15-20% of PMCs, and 
treatment at the time of tumor injection with an MMP-9 inhibitor reduced metastasis.[171]  
Others have found that the reduction in metastasis also extended to mice deficient in the 
CCR5 ligand CCL3, and that WT lungs accumulated more monocytes, T cells, and 
28 
 
fibroblasts than CCR5
-/-
 or CCL3
-/-
 lungs, as well as more production of MMP-9 and 
HGF.[159]  Therefore CCR5 signaling is important for the formation of pro-metastatic 
stroma.  The further investigate the mechanisms for this finding, we compared gene 
expression in WT vs. CCR5
-/-
 lungs after B16-F10 melanoma cell injection. 
 Erythroid Differentiation Regulator 1 (Erdr1) has not previously been associated with 
tumor growth, metastasis, or chemokine signaling.  It was first isolated as a cytokine released 
by the myelomonocytic cell line WEHI-3B that induced hemoglobin synthesis. [175]  Further 
investigation found Erdr1 expression in the murine embryonic fibroblast cell line NIH-3T3, 
primary murine lymphoma lysates, and human CD34
+
 enriched peripheral blood 
mononuclear cells (PBMCs).[175]  It was found to be released under a number of different 
conditions of cell stress, and it acted as a survival factor for a Burkitt’s lymphoma cell line as 
well as for erythroblast and granulocyte/monocyte progenitors.[176]  When expressed in 
hematopoietic stem cells (HSCs), Erdr1 similarly promoted their expansion and inhibited 
apoptosis, as well as promoting their ability to repopulate bone marrow in vivo.[183]  Erdr1 
expression has been correlated with a number of cell types and biological processes by 
cDNA microarrays, including HSCs[178, 179], stromal cells[184](GEO Dataset GDS2421), 
brain inflammation and neurodegenration[108, 187-189], innate and adaptive immunity[190-
192], and development [193-195]. 
Here we show a novel function of Erdr1, which is induced after the binding of ligand 
to CCR5 on stromal cells.  This activity results in the promotion of lung metastasis by 
stromal cells in vivo and their enhanced survival in vitro.   Thus, Erdr1 may be a novel target 
for the prevention of lung metastasis clinically.    
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IV. Results 
 
Genes differentially expressed in WT vs. CCR5 
-/-
 lungs 
We have previously shown that CCR5
-/-
 mice develop fewer metastases than WT 
mice.  To identify genes which might mediate CCR5-dependant promotion of metastasis, we 
injected B16-F10 melanoma cells into WT or CCR5 
-/-
 mice intravenously and harvested lung 
RNA 6, 24, and 48 hours later for Affymetrix expression analysis.  cDNA was pooled at each 
time point from 4 or 5 mice of each genotype.  We found 11 candidate genes differentially 
expressed by WT vs. CCR5
-/-
 lungs at all three time points (Fig. 2.1A).  Of these, Mid1, 
Erdr1, and Ccr9 had more than a two-fold higher expression and Clca3 and Tna had a more 
than 2-fold lower expression in WT compared to CCR5
-/-
 mice.  To confirm the expression 
data found by cDNA microarray, semi-quantitative RT-PCR was performed for the 11 
candidate genes using cDNA from each mouse.  The expression of most of these genes 
displayed significant variability (Fig. 2.S1), and of the 5 genes with more than two-fold 
differential expression by microarray, only the expression of Erdr1 was significantly different 
by densitometry (Fig. 2.1B) at all time points analyzed.  Erdr1 expression was similar in all 
WT mice and near or below the level of detection for all CCR5
-/-
 mice (Fig. 2.1C).  
Therefore, we chose to further characterize the role of Erdr1 in the promotion of lung 
metastasis. 
 
Erdr1 expression in pulmonary mesenchymal cells 
Since previous work demonstrated that the reduction of metastases in CCR5 
-/-
 mice 
can be reversed by the transfer of WT but not CCR5 
-/-
 PMCs [170], Erdr1 expression was 
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measured in cultured PMCs.  By real time RT-PCR, Erdr1 expression in WT PMCs was 6.4 
±
 
2.7 -fold higher than in CCR5
-/-
 PMCs (Fig. 2.2A) (p < 0.001).  The higher production of 
Erdr1 in WT PMCs was confirmed by Western Blot (Fig. 2.2B).  Cultured PMCs contain 
three different populations of stromal cells, which can be defined by expression of CD45 and 
Thy1.  To determine the expression of Erdr1 by each individual population, WT and CCR5
-/-
 
PMCs were sorted for these different populations, and Erdr1 expression was analyzed by real 
time RT-PCR.  WT PMCs from the CD45
+
 (fibrocyte), Thy1
+
CD45
-
, and Thy1
-
CD45
-
 
populations all expressed more Erdr1 than their CCR5
-/-
 equivalents (Fig. 2.2C) (p < 0.005, p 
< 0.05, p < 0.005, respectively).  There was also significantly more Erdr1 expression relative 
to Sdh in WT Thy1-CD45- PMCs than in WT fibrocytes (0.49 vs 0.24, p < 0.05) or in WT 
Thy1
+
CD45
- 
PMCs (0.49 vs. 0.32, p < 0.05).  These differences were not seen between the 
PMC populations from CCR5
-/-
 mice.  
Erdr1 was originally cloned by Dormer et al. from the myelomonocytic cell line 
WEHI-3B [175](accession A539223), and the current reference sequence was cloned by the 
Mammalian Gene Collection Program Team from a murine mammary tumor [196](accession 
NM_133362).  There are a few differences between the sequences from these two different 
cell types, in both the nucleotide and amino acid sequences.  To determine whether PMCs 
expressed similar transcripts to either of these, we compared the sequence of the cDNA 
isolated from PMCs of WT animals to that previously found in WEHI-2B or a mouse 
mammary tumor cell line.  As shown in Fig. 2.S2, the ORF in the Erdr1 consensus sequence 
isolated from PMCs was 100% homologous to the sequence found in the WEHI-3B cell line 
(sequence AJ539223).   
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Induction of Erdr1 expression by CCL4 
To determine whether CCR5 signaling induced expression of Erdr1, WT and CCR5 
-/-
 
PMCs were stimulated with the CCR5-specific chemokine, CCL4.  As measured by real time 
PCR, Erdr1 was induced by CCL4 at 24 hrs (1.33 -fold 
±
 0.06, p < 0.05) and 48 hrs (3.36 -
fold 
±
 0.14, p < 0.0005)(Fig. 2.3A) in WT PMCs.  Erdr1 was not induced by CCL4 in CCR5 
-
/-
 PMCs. The difference between fold Erdr1 induction in WT and CCR5 
-/-
 CCL4 treated 
PMCs from 3 separate experiments was statistically significant (Fig. 2.3B, p < 0.05), 
indicating that ligand binding to CCR5 up-regulates the expression of Erdr1.  We further 
confirmed these findings by Western blot (Fig. 2.3C).  We then tested the capacity of CCL4 
to induce Erdr1in sub-populations of PMCs.  In these experiments, PMC cultures were sorted 
by Thy1 and CD45 expression (Fig. 2.3D) after 48 hours of treatment with CCL4.  A 14.2 -
fold 
±
 2.9 increase of Erdr1 expression was seen in WT CD45
+
 fibrocytes, but not in CCR5
-/-
 
fibrocytes (p < 0.01 for CCL4 vs. media and p < 0.01 for WT vs. CCR5
-/-
) (Fig. 2.3E).  Other 
fold differences between populations upon CCL4 stimulation were not statistically 
significant. 
 
Reduction in Metastasis after Erdr1 Knockdown 
To investigate the role of Erdr1 in metastasis we first used murine embryonic 
fibroblasts (MEFs).  We determined that like PMCs, MEFs promoted metastasis in CCR5
-/-
 
mice (Fig. 2.4A) and expressed Erdr1 (Fig. 2.S3A&B).  We constructed two HSPG retroviral 
vectors carrying different Erdr1-specific short hairpin RNA (shRNA) sequences which we 
had previously determined effective by transfection (data not shown), as well as one vector 
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carrying a “No Target” shRNA control (Fig. 2.S3C).  By measuring the fluorescence of GFP 
co-expressed by the vectors, we found that they efficiently transduced MEFs (Fig. 2.4B).  
These were initially sorted by GFP expression to separate the non-transduced cells.  The two 
Erdr1-targeted shRNA vectors reduced Erdr1 expression by 89.2% 
±
 2.5% and 99.5% 
±
 2.5% 
relative to the no target shRNA vector (Fig. 2.S3D).  However, the sort-purified Erdr1 
knockdown MEFs did not expand in vitro, and thus could not be used for in vivo studies.  As 
a result, shRNA transduced MEFs were used 48 to 72 hours after transduction without 
separating GFP
+
 from GFP
-
 cells.  Figures 2.4B and 2.4C show a representative culture of 
Erdr1 knockdown lines with a transduction efficiency of approximately 70% and a 
knockdown efficiency of 55.9% 
±
 1.1% for shRNA #1 and 68.8% 
±
 6.5% for shRNA #2.  
Knockdown of Erdr1 was further confirmed by Western blot (Fig. 2.4D). 
In order to test Erdr1 effect on metastasis, CCR5
-/-
 mice were intravenously injected 
with Erdr1 knockdown MEFs 48 hours prior to injection of B16-F10 melanoma cells.  As 
shown in figure 2.5A, the knockdown of Erdr1 led to a 32.6% and 32.2% decrease in lung 
metastasis from B16-F10 tumor cells fourteen days after the injection of tumor cells (p < 0.05 
for both shRNA constructs).  The range of transduction efficiency of the MEFs varied for 
each of these experiments and this could have diminished the effect found after knocking 
down the expression of Erdr1.  Thus, we grouped recipient mice into those in which the 
transduction efficiency was > 50% and those with a transduction efficiency of < 50%.    As 
shown in Fig. 2.5B, there was a 46.6% and 50.4% reduction in metastasis in the > 50% 
transduced group (p < 0.05 for both) and only a 23.8% and 24.3% reduction in the group in 
which less than 50% of the cells were transduced, which was not statistically significant.  
Conversely, when Erdr1 knockdown lines were transferred to WT mice prior to tumor 
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injection, there was no reduction in metastases compared to the group receiving control 
shRNA MEFs (Fig. 2.5C), which is similar to our findings transferring PMCs to wild type 
mice.  Thus, these data demonstrate that Erdr1 expression is important for the growth of B16-
F10 tumor cells in a metastatic lung model.  Our finding that the level of transduction and as 
a result the knockdown of Erdr1 corresponded to the in vivo reduction of tumor metastases 
strongly suggests that this finding is not a result of off target effects.   
 
Overexpression of Erdr1 sequence induces cell death. 
 To confirm our findings using shRNA targeting Erdr1, we sought to overexpress 
Erdr1 in CCR5
-/-
 PMCs.  Therefore, we cloned Erdr1 into a lentiviral vector and tested its 
function.  Two different constructs were generated using a strong promoter from CMV and a 
weaker promoter E2F1.   
 A293T cells, which express very low Erdr1, were transfected first with the expression 
plasmids alone, without packaging plasmids.  As shown in Fig. 2.6A, this increased 
production of Erdr1 mRNA by at least 100-fold.  A 100-fold increase was also seen in PMCs 
transduced with either Erdr1 expressing lentivirus (Fig. 2.6B).  However, this magnitude of 
expression rapidly led to cell death, not only of the transduced cells, but of the neighboring 
cells (Fig. 2.6C).  These data are consistent with the previous report that at high 
concentrations Erdr1 ceases to promote survival and instead induces cell death.[176]  Thus, 
we were not able to generate a cell line that persisted after overexpression using either 
promoter and were unable to evaluate the effects of the overexpression of Erdr1 in vivo.  
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Induction of Apoptosis by Erdr1 Knockdown 
Given the failure of sort-purified Erdr1 knockdown MEFs to expand in vitro, 
apoptosis in these lines was measured by flow cytometry using staining with Annexin-V  48 
hours after transduction (Passage 1).  At this time, there were only slight differences in 
percent apoptotic cells between Erdr1 knockdown MEFs (9.6% and 11.7%) and control 
shRNA MEFs (8.2%) (Fig. 2.7A).  However, the ratio of Annexin-V cells in the knockdown 
vs. control MEFs increased over two further passages, reaching 1.7-fold and 2.8-fold (Fig. 
2.7B).  To determine whether Erdr1 knockdown would have the same effect in primary 
PMCs, these cells were transduced with the shRNA vectors and apoptosis was measured as 
before.  Transduction efficiency in these cells was 48.1% for No Target shRNA, 43.4% for 
Erdr1 shRNA#1, and 61.0% for Erdr1 shRNA#2.  As seen with the MEFs, PMCs transduced 
with the knock down shRNA had 3.1 and 2.5 -fold more apoptotic cells at passage 3 than the 
No Target shRNA line (Fig. 2.7C).  Additionally, Erdr1 knockdown PMCs did not 
significantly expand (Fig. 2.7D).  When measuring fold expansion over 15 days, No Target 
shRNA PMCs expanded 28.3 -fold while the two knockdown PMC cultures expanded a 
modest 1.17 -fold and 0.85 -fold.  We next tested whether the increased apoptosis was 
capsase mediated, using the pan-caspase inhibitor Z-VAD-FMK.  Fourteen days of treatment 
with mock inhibitor increased the percent apoptotic cells in Erdr1 knockdown PMCs to 
approximately 67%, while only 28% of the No Target shRNA transduced PMCs were 
apoptotic with mock inhibitor (Fig. 2.7E) (p < 0.05 for both knockdown PMCs vs. No Target 
shRNA PMCs).  Z-VAD-FMK reduced No Target shRNA PMC apoptosis to that of the 
media alone group (12.9%), and partially reduced the percent of apoptotic Erdr1 knockdown 
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PMCs (to 27%, p < 0.01, and 37%, not significant, vs. mock inhibitor).  Z-VAD-FMK also 
partially restored the ability of Erdr1 knockdown PMCs to expand in vitro (Fig. 2.7F). 
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V. Discussion 
 
Metastasis is the most common cause of death for patients with cancer.  This complex 
process requires that tumor cells migrate into and grow in distant tissue, which is dependent 
on cross-talk between the tissue stroma and the migrating tumor cells.  However, designing 
strategies to disrupt this interaction have been difficult due to the lack of suitable stromal cell 
targets.  Previously our group has shown that CCR5 signaling in stromal cells played a role 
in this process[170], and further investigation suggested that this role was early in the process 
of colonization, and partly involved MMP-9[171].   We hypothesized that other stromal 
genes involved in early colonization would be differentially expressed in the lungs of CCR5
-/-
 
mice after tumor injection, and designed the microarray experiment presented here to identify 
such potential targets.  Our data identify Erdr1 as a pro-metastatic stromal cell survival factor 
regulated by CCR5. 
We limited our study to genes differentially expressed at 6, 24, and 48 hours after 
tumor injection, and 5 of the 11 genes that met this criteria were differentially expressed 
more than two-fold at all three times.  Mid1 is the developmental gene implicated in X-linked 
Opitz G/BBB syndrome[197], and its expression has recently been reported to be predictive 
for colorectal carcinoma metastasis[198].  Ccr9 is the gene for a chemokine receptor that 
multiple groups have linked to metastasis[199-201], as well as tumor growth [202, 203].  
Tna, also known as tetranectin, was upregulated in CCR5
-/-
 vs. WT mice in our study, but it 
has nevertheless been known for many years to be expressed in tumor stroma[204], and has 
more recently been associated with poor prognosis in a number of cancers[205-207]  Also 
upregulated in CCR5
-/-
  vs. WT lungs after tumor injection, Clca3 is involved in immune 
responses induced by the Th2 cytokines IL-9 and IL-13, in both the lung and the colon[208, 
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209].  While any of these genes may be involved in early metastasis formation, which our 
pooled microarray data would support, we found their differential expression was not 
consistent between individual mice by semi-quatitative real time RT-PCR.  This may be due 
to transient or context-dependent expression, or they may not be significantly linked to the 
role of CCR5 in metastasis. 
On the other hand, we found Erdr1 to be consistently upregulated in WT lungs 
relative to CCR5
-/-
 lungs during the first 48 hours after tumor injection.  Furthermore, 
cultured PMCs from WT mice expressed more Erdr1 than CCR5
-/-
 PMCs in every assay 
performed.  This differential expression was seen not only in the CD45
+
 fibrocyte population, 
which has been shown to respond to CCR5 stimulation[171], but also in CD45
-
 PMCs.  This 
could be explained by constitutive low-level expression of CCR5 on CD45
-
 PMCs in 
combination with constitutive autocrine or paracrine chemokine release.  Alternatively, 
CD45- PMCs could be “programmed” to express Erdr1 by CCR5 stimulation during 
differentiation from fibrocytes or mesenchymal stem cells, which also express CCR5[210].  
The fact that Erdr1 is higher in WT PMCs even before contact with tumor cells suggests that 
its role in the lung is not necessarily limited to the period of early metastasis measured by our 
array, nor is it necessarily limited to metastasis.  For instance, it may be involved in other 
processes dependent on CCR5 signaling in stromal cells, like experimentally induced 
pulmonary fibrosis.[45]  In any case, these data are the first to demonstrate that Erdr1 
expression is linked to ligand binding to CCR5. 
Besides constitutive differential expression, our data also establish that stimulation of 
CCR5 on PMCs increases Erdr1 expression.  The induction was largely confined to the 
CD45
+
 fibrocyte population, as expected based on expression of CCR5.  That fibrocytes 
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responded to CCR5 stimulation by expressing Erdr1 is particularly relevant given our 
previous data suggesting fibrocytes encounter and respond to CCR5 ligands in the lung 
during metastasis formation.  Even given constitutive tissue stromal production of Erdr1, a 
local increase mediated by fibrocytes migrating into the new tumor site might then assist the 
formation of a tumor-supportive stroma.   
To test the effect of knocking down Erdr1 in intravenously transferred stromal cells, 
we used MEFs rather than PMCs due to their greater ability to expand in culture, their 
phenotypic stability over several passages in culture, and the increased expression of Erdr1 in 
MEFs compared to PMCs.  Initially, we confirmed the ability of MEFs to promote metastasis 
in vivo.  We attempted to pursue similar studies using PMCs with the knockdown vectors 
described.  However, Erdr1 is critical for the prevention of apoptosis in these cells and as a 
consequence, we were not able to generate a viable population of PMCs after transduction 
with vectors knocking down the expression of  Erdr1 to do this analysis.  A second approach, 
the generation of bone marrow chimeras using bone marrow cells transduced with 
lentiviruses expression shRNA for Erdr1, is complicated by the extremely slow turnover 
from bone marrow cells of fibrocytes.  At this time, it is not clear when, if ever, all of the 
fibrocytes would convert from recipient to donor after transplantation.  
When injected into mice prior to tumor injection, Erdr1 knockdown MEFs promoted 
fewer metastases than control shRNA MEFs in CCR5
-/-
 but not WT mice.  This is consistent 
with our previous finding that WT PMCs promoted metastasis in CCR5
-/-
 mice, but CCR5
-/-
 
PMCs had no effect on metastasis in WT mice.  Expression of Erdr1 in WT lungs may make 
the differences in Erdr1 expression between knockdown and control shRNA MEFs irrelevant 
to the process of metastasis.  In CCR5
-/-
 mice, however, the difference between lung Erdr1 
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content between groups was much larger, which may be critical to the observed effect on 
metastasis.  We attribute some of the differences in metastasis promotion to the ability of 
Erdr1 to support survival of stromal cells.  Knockdown of Erdr1 led to the gradual 
accumulation of apoptotic MEFs in vitro, and to a greater extent, of PMCs.  The large 
increase in knockdown PMC apoptosis observed after incubation with a mock caspase 
inhibitor and 0.2% DMSO underscores the inability of these cells to cope with stress.  
Dormer et al. reported that murine erythroleukemia cells released Erdr1 when exposed to 
DMSO, as well as under other conditions of stress.[176]  Therefore, the generation and 
release of Erdr1 may be an important anti-apoptotic response such stimuli.   
Our data is not consistent with Erdr1 generating a proliferative advantage in stromal 
cells.  Significant overexpression of Erdr1 by lentiviral vectors induced death of MEFs in 
culture.  Thus, Erdr1 in both the Burkitt lymphoma cell line BL-70 and in primary fibroblasts 
appears to support both cellular survival and death depending on the degree of expression.  It 
is possible that much lower expression of Erdr1 would enhance stromal cell proliferation 
although we were not able to demonstrate that.   
One alternative explanation for our findings is that the knockdown of Erdr1 led to the 
injection of a greater number of apoptotic stromal cells compared to mock knockdown 
MEFs.  We believe this is unlikely for two reasons.  First, MEFs were injected 48 hours after 
transduction, at which time the percentage of apoptotic cells knockdown lines were still 
similar to the percentage in the No Target MEFs.  Second, there was no difference in 
metastasis after injection of WT mice with knockdown MEFs, which would be expected if 
the small differences in apoptosis were inhibiting metastasis.   
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Rather, we propose that expression of Erdr1 allows MEFs to persist longer in the 
lungs after injection and promote the formation of tumor-supporting stroma.  In the case of 
our previous study, induction of Erdr1 through stimulation of CCR5 on migrating fibrocytes 
would lead to locally higher concentration, thus supporting the formation of supportive 
stroma.  In the case of natural in vivo metastasis a similar process may occur, whereby the 
colonization of tissues by metastatic nodules induces the migration of CCR5
+
 fibrocytes and 
other CCR5
+
 bone marrow-derived cells, which then produce Erdr1 locally to support the 
tumor stroma.  A recent study identifying Erdr1 as a survival factor for (HSCs)[183] is 
particularly relevant here, given that HSCs have also been implicated in the formation of pro-
metastatic stroma[211]. 
The ongoing investigation in our laboratory of important aspects of Erdr1 function 
faces a number of challenges. The protein does not contain any of the known protein-protein 
domains or sequences critical for nuclear import or cellular secretion.  A receptor for 
mediating the activity of Erdr1 has not been identified.  The promoter is not known and the 
gene does not map currently to any part of the human genome although it has been shown to 
be expressed by multiple human cells.  Array data suggests a critical role for Erdr1 during 
embryogenesis.  Whether the anti-apoptotic role of Erdr1 is critical in this process is not clear 
at this time.   
These findings identify Erdr1 as a cytokine important to the survival of peri-tumoral 
stromal cells.  Furthermore, they establish an additional means by which inflammatory 
chemokines contribute to cancer progression.  These data suggest that CCR5 may be a viable 
target for the prevention of tumor metastasis.  Finally, our data suggest that this relatively 
unknown gene may be critical to understanding and manipulating tumor-stroma interactions.  
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VI. Experimental Procedures 
 
Mice 
C57BL/6J (WT) mice were purchased from Jackson Laboratories.  CCR5
-/-
 mice have 
been described previously.[212]  All animals were housed in pathogen free conditions and 
animal experiments were conducted using protocols approved by the Institutional Animal 
Care and Use Committee of the University of North Carolina at Chapel Hill. 
Cells 
Isolation of pulmonary mesenchymal cells (PMCs) was performed as previously 
described[171].  In all experiments, PMCs were used within 2 passages.  Murine embryonic 
fibroblasts (MEFs) were harvested from day E 13.5 embryos as described elsewhere [213] 
and were transduced following 2 and 5 ex vivo passages.  All cell types were cultured in 
DMEM supplemented with 10% FBS and 1% penicillin/streptomycin.  B16-F10 melanoma 
and A293T cells were purchased (American Type Culture Collection). 
In Vivo Experiments 
4x10
5
 MEFs were transferred to mice by intravenous tail-vein injection.  48 hours 
later, 7.5 x 10
5
 B16-F10 cells were injected intravenously.  14 days after tumor cell injection, 
mice were anesthesized by intraperitoneal injection of avertin, lungs were perfused with PBS, 
and the left lung was excised and fixed in Fekete’s solution.  Surface metastatic nodules were 
counted by an individual blinded to the experimental group.   
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Microarray Expression Analysis 
Lungs from WT or CCR5 
-/-
 mice were harvested at 6, 24, and 48 hours after 
intravenous injection of 7.5 x 10
5
 B16-F10 melanoma cells (4 to 6 mice per group).  RNA 
was isolated and reverse transcribed.  The resulting cDNA from each group was pooled and 
hybridized to Affymetrix  gene chips (6 chips total).  Gene expression was analyzed using 
GeneSpring software.  Confirmation of the overexpression of genes found from the 
microarray studies was performed using semi-quantitative RT-PCR.  Primer sequences used 
are available in Supplementary Experimental Procedures. 
Cytokine Stimulation 
PMCs were cultured for 12 hours in serum-free DMEM, and then stimulated with 100 
ng/mL of CCL4 (Peprotech).  Serum-free media was replaced with 10% media 24 hours after 
stimulation; cells were harvested for RNA isolation 48 hours after stimulation. 
 RT-PCR and Western Blots 
PMC or MEF RNA was isolated using the RNeasy Plus kit (Qiagen) and cDNA was 
reverse transcribed at 50  C using Superscript III (Invitrogen) and oligo-dT.  Remaining 
mRNA was degraded by RNAse H (Promega).  Real Time PCR was performed using SYBR 
Green Master Mix, and Erdr1 expression was calculated relative to -actin or SDH .  Erdr1 
specific primers were: Forward 5’-CCGCCGCGGTCAAGATGTATGT-3’ and Reverse 5’-
TTGACCACGGCGTCCGCTTCT A-3’.  The -actin specific primers were Forward  5’-
TTCTTTGCAGCTCCTTCGTT-3’ and Reverse 5’-GAGTCCTTCTGACCCATTC-3’.  The 
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Sdh specific primers were Forward  5’-GGAACACTCCAAAAACAGACCT-3’ and 
Reverse 5’-CCACCACTGGGTATTGAGTAGAA-3’. Western blots were performed on 
whole cell lysates separated by 4-12% SDS-PAGE (Invitrogen), blocked with 3% bovine 
serum albumin, and probed with the Erdr1 specific rat antibody 8A12 (Ascenion).  The rabbit 
anti-GAPDH antibody (sc-25778, Santa Cruz) was used as a loading control.  HRP-
conjugated goat anti-rat IgG (18-4818-82, Ebioscience) or donkey anti-rabbit IgG (18-8816-
31, Ebioscience) were used as secondary antibodies, and blots were developed using an ECL 
kit (Amersham). 
Cloning and Sequencing 
Erdr1 was amplified from PMC and MEF cDNA using Accuprime GC Rich 
Polymerase (Invitrogen), with the primers (forward) 5’-GACCGTGCGGACTTAAGATGG-
3’ and (reverse) 5’-TTATTGAGGGGGGGCATTTCTGTA-3’, and 40 cycles of 95 oC for 30 
sec, 60 
o
C for 30 sec, and 72 
o
C for 2 min (adapted from [175]).  PCR products were cloned 
into pCR-BluntII-TOPO (Invitrogen) and transformed into TOP10 cells (Invitrogen).  
Kanamycin resistant clones were screened for inserts by EcoRI digestion (New England 
Biolabs) and sequenced by the UNC Genome Analysis Facility using the primers provided 
by the manufacturer.  For expression by lentiviral vectors, Erdr1 cDNA was cloned into 
pLenti7.3 (Invitrogen).  Another pLenti7.3 construct with an EF-1 promoter was obtained 
by a restriction cloning strategy, involving the removal of the CMV promoter from 
pLenti7.3-Erdr1, the removal of the EF-1 promoter from pEF-DEST (Invitrogen), and the 
ligation of the EF-1 promoter into the promoterless pLenti7.3-Erdr1 plasmid.  Lentiviral 
vectors were packaged in 293T cells according to the manufacturer’s instructions. 
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Flow cytometry and cell sorting 
For identification of PMC populations, cells were harvested by trypsinization and 
resuspended in PBS with 2% FCS, then incubated with anti-Thy1.2-PECy7 (eBioscience) 
and anti-CD45-eFluor450 (eBioscience) antibodies for 15 min. at room temperature.  CD45
+
 
cells were sorted by the UNC Flow Cytometry Facility.  For identification of apoptotic cells, 
PMCs or MEFs were resuspended in Annexin-V binding buffer and stained with propidium 
iodide (eBioscience) and Annexin-V- APC (eBioscience) for 15 min at room temperature.  
Fluorescence was measured on the MACSQuant Analyzer (Miltenyi), and further analyzed 
using Summit software (Beckman Coulter). 
Generation and use of shRNA retroviral vectors 
One control shRNA sequence designed not to target any known gene, and two 
shRNA sequences targeting Erdr1, based on siRNA sequences from Dharmacon (No Target 
shRNA: D-001810-01-05, Erdr1 shRNA #1:  J-053706-09, Erdr1 shRNA #2: J-053706-11) 
that were validated for knockdown efficiency, were cloned into pHSPG vector [214, 215] 
driven by an histone H1 promoter.  The shRNA sequences were confirmed by the UNC 
Genome Analysis facility.  The pHSPG shRNA constructs were co-transfected with plasmids 
containing the VSV-G and gag/pol genes into A293T cells by calcium phosphate transfection 
as described [215].  Supernatant containing recombinant virus was harvested at various time 
points between 36 and 72 hours post-transfection and passed through a 0.45 micron filter.  
The packaged shRNA virus was concentrated by centrifuging at 24,000 rpm for 3 hours at 4
o 
C and followed by re-suspension in PBS.  Viral titer was determined by transducing NIH 3T3 
cells and assaying for GFP expression by flow cytometry 48 hours after transduction.  PMCs 
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or MEFS were transduced in 6-well plates by adding polybrene (4 g/mL) and virus 
(MOI=5) to the media and centrifuging the plates at 1000 X g for 1.5 hours.  Media was 
replaced with fresh media after 24 hours, and transduction efficiency (% GFP
+
) was 
measured by flow cytometry 48 hours post-transduction. 
Statistics 
Unless otherwise stated, data are presented as the mean of measurements taken from 
three or more separate experiments.  Statistical error for these means is presented as +1 SEM.   
p values were determined by Student’s T-Test, and values < 0.05 were considered significant.    
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VII. Figures 
  
Figure 2.1  Erdr1 is upregulated in WT vs. CCR5
-/-
 lungs after IV tumor injection. 
Lungs were harvested 6, 24, and 48 hr after IV B16-F10 injection, and RNA was 
immediately isolated for Affymetrix array and RT- PCR.  A. Genes differentially expressed 
in WT vs. CCR5 
-/-
 lungs at all three time points, measured by Affymetrix array.  RNA was 
pooled from the lungs of mice in each group at each time point.  B. Semi-quantitaive RT-
PCR using primers for genes differentially expressed by more than 2-fold on the Affymetrix 
array.  Numbers represent averages of densitometry values for RT-PCR of lung RNA from 
the individual mice used in the Affymetrix array.  Error bars represent 
±
  SEM.  * p < 0.05 for 
WT vs. CCR5
-/-
  All other differences were not statistically significant.  C. Semi-quantitative 
RT-PCR for Erdr1, showing consistent differential expression for all mice at all time points.   
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Figure 2.2  Erdr1 is upregulated in WT vs. CCR5
-/-
 PMCs in culture. 
PMCs were cultured from perfused WT or CCR5-/- lungs for 2-3 passages, and then 
harvested for RNA and protein analysis.  A. Erdr1 expression relative to CCR5
-/-
 PMCs by 
real time RT-PCR.  Erdr1 expression was normalized to -actin.  Results averaged from 3 
separate concurrent cultures of WT and CCR5
-/-
 PMCs.  B. Erdr1 protein expression in WT 
and CCR5
-/-
 PMCs by Western blot.  C. Differential Erdr1 expression in WT and CCR5 
-/-
 
PMC populations by real time RT-PCR, relative to SDH.  Error bars represent ±  SEM.  * p 
< 0.005 for WT vs. CCR5
-/-
   # p < 0.05 for WT vs. CCR5
-/-    ‡ p < 0.05 for WT CD45-Thy1- 
vs. WT CD45
+
. 
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Figure 2.3  Stimulation of CCR5 on PMCs induces expression of Erdr1. 
WT and CCR5
-/-
 PMCs were stimulated with CCL4 or media alone and harvested after the given intervals for RNA 
analysis.  A. Erdr1 expression at 0, 24, 48 hr after addition of CCL4 by real time RT-PCR.  * p < 0.05 for CCL4 vs. 
media  # p < 0.005 for CCL4 vs. media.  B. Fold induction of Erdr1 at 48 hours after CCL4 stimulation.  Numbers 
represent the mean of 3 separate experiments.  * p < 0.05 for WT vs. CCR5
-/-
.  C. Flow cytometric analysis of PMC 
populations sorted by CD45 and Thy1 expression for Erdr1 real time RT-PCR.  D. Fold induction of Erdr1 in sorted 
PMC populations.  PMCs were sorted 48 hours after stimulation with CCL4.  ‡ p < 0.01  Error bars represent ± 1 
SEM.   
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Figure 2.4  MEFs promote metastasis and shRNA reduces Erdr1 expression in MEFs.   
A. Metastasis formation in WT and CCR5
-/-
 mice, and CCR5
-/-
 mice were injected with 
MEFs prior to B16-F10 injection, relative to the mean number of metastases in WT mice.  * 
p < 0.001 for WT vs. CCR5
-/-
  # p < 0.001 for CCR5
-/-
 vs. CCR5
-/-
 + MEFs.  Metastasis in 
WT vs. CCR5
-/-
 + MEFs was not statistically significant (p = 0.09).  B. Percent GFP
+
 cells in 
MEF cultures transduced with shRNA retroviral constructs 48 hours after transduction.  C. 
Erdr1 expression in MEFs cultures transduced with shRNA retroviral constructs by real time 
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RT-PCR 48 hours after transduction.  Error bars represent 
±
 1 SEM.   ‡ p < 0.05 vs. No 
Target shRNA.  D. Erdr1 protein expression in MEFs cultures transduced with shRNA 
retroviral constructs by Western blot.   
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Figure 2.5  Erdr1 knockdown MEFs promote fewer metastases in CCR5 
-/-
, but not WT 
mice. 
MEFs were transduced with Erdr1 targeting or No Target shRNA expressing retroviral 
vectors, and injected into mice 48 – 72 hours after transduction.  B16-F10 cells were injected 
48 hours later, and mice were harvested after 14 days for enumeration of metastases in the 
left lung.  A. Metastases in lungs of CCR5
-/-
 mice injected with shRNA transduced MEFs 
prior to B16-F10 injection, relative to mean number of metastases in the No Target shRNA 
group for each experiment.  Results pooled from 3 separate experiments.  * p < 0.05 vs. No 
Target shRNA.  B. Metastases in lungs of CCR5
-/-
 mice injected with shRNA transduced 
MEFs prior to B16-F10 injection, analysed by transduction efficiency of the injected MEFs.  
Expressed as relative to mean number of metastases in the No Target shRNA group for each 
experiment.  Results pooled from 3 separate experiments.  * p < 0.05 vs. No Target shRNA.  
Mean relative metastasis in < 50% transduction groups were not statistically different from 
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No Target shRNA (p = 0.10 and p = 0.15).  C. Metastases in lungs of WT mice injected with 
shRNA transduced MEFs prior to B16-F10 injection, relative to mean number of metastases 
in the No Target shRNA group.  D. Lungs of CCR5
-/-
 mice injected with shRNA transduced 
MEFs prior to B16-F10 injection, from an experiment with > 50% transduction. 
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Figure 2.6  Erdr1 Overexpression leads to rapid cell death in vitro. 
A. Erdr1 expression in transfected A293Ts, relative to A293T + empty plasmid.  B. Erdr1 
expression in lentivirus transduced PMCs, relative to empty vector.  C. Enumeration of 
MEFs at 8, 24, and 48 hours post-transduction.  GFP expression indicates transduced cell. 
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Figure 2.7  Erdr1 knockdown induces apoptosis in MEFs and PMCs.  
A. Apoptosis in Erdr1 knockdown MEFs 48 hr after transduction (passage 1) by staining 
with Annexin-V and PI.  B. Apoptosis in Erdr1 knockdown MEFs over 3 passages after 
transduction, expressed as fold difference in % Annexin-V
+
 cells relative to No Target 
shRNA.  C. Apoptosis in Erdr1 knockdown PMCs over 3 passages after transduction, 
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expressed as fold difference in % Annexin-V
+
 cells relative to No Target shRNA.   D. Cell 
number in Erdr1 knockdown PMC cultures over 3 passages (15 days) after transduction.  E. 
Effect of caspase inhibition on Erdr1 knockdown PMC apoptosis.  PMCs were transduced 
with Erdr1 knockdown or No Target shRNA, and treated with media, a pan caspase inhibitor 
(Z-VAD-FMK), or a mock inhibitor (Z-FA-FMK) every 3 days, and analyzed after 14 days.  
F. Effect of caspase inhibition on Erdr1 knockdown PMC fold expansion. 
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VIII. Supplementary Figures 
 
Figure 2.S1  Semi-quantitative RT-PCR for genes differentially regulated at all 3 time 
points by Affymetrix array.  
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Figure 2.S2  Sequence alignment for the consensus Erdr1 sequence from PMC cDNA 
with published sequences.  
The consensus sequence was derived from more than 20 clones, and from different PMC 
cultures. 
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Figure 2.S3  Erdr1 expression in MEFs.  
A. Erdr1 expression in WT and CCR5
-/-
 MEFs and PMCs by real time RT-PCR, expressed 
relative to WT PMCs.  All groups were statistically significantly different from each other.  
B. Erdr1 protein expression in WT and CCR5-/- MEFs and PMCs by Western blot.  C. Map 
of retroviral construct used for shRNA knockdown, and shRNA sequences.  D. Erdr1 
expression in sort-purified MEFs transduced with shRNA retroviral constructs and sorted 48 
hours after transduction.  Real time RT-PCR results expressed relative to No Target shRNA.  
Error bars represent ± 1 SEM  * p < 0.01
  
Chapter 3 
Molecular Characterization of Erythroid Differentiation 
Regulator 1 
 
I.  Abstract 
 
 Erythroid Differentiation Regulator 1 (Erdr1) has been shown to induce hemoglobin 
synthesis, to promote the proliferation and prevent apoptosis of cell lines, and to promote 
hematopoietic stem cell activity.  We have recently found that Erdr1 promotes metastasis as a 
stromal cell survival factor, and is induced upon stimulation of the chemokine receptor 
CCR5.  Though evidence concerning the functions of Erdr1 is building, many questions 
about its molecular biology remain, particularly with regard to its existence in humans.  This 
chapter will discuss the molecular characterization of Erdr1.  We have found Erdr1 
expression in multiple murine and human cell lines and primary cells.  The description of the 
initial isolation of Erdr1 refers to high variability in the 5’ end of RNA transcripts.  The 
sequence we obtained from pulmonary mesenchymal cell cDNA differed from the published 
sequences in that region, as previously described.  We also found multiple products by 5’ 
RACE without start sites, consistent with other observations that many Erdr1 mRNA 
sequences do not contain open reading frames (ORFs).   Using a combinatorial primer 
approach, we show that an identical ORF was expressed in the human Raji cell line, as well 
as in primary nurse-like cells from CLL patients.  These data demonstrate that the ORF found 
in PMCs expresses a protein and is conserved in both mice and humans. 
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II. Introduction 
 
 Evidence is growing that Erdr1 plays a role in multiple biological processes such as 
induction of hemoglobin in erythroleukemia cells[175], survival of Burkitt’s lymphoma cells 
and erythroid and granunlocyte/monocyte progenitors[176], enhancement of hematopoietic 
stem cell repopulation[183], and promotion of metastasis by stromal cells (see Chapter 2).  It 
has also been associated with many other processes through expression array studies.  
However, there are still currently many questions about this gene that must be addressed 
before these findings can be of clinical benefit.  For example, though its expression has been 
reported in human cells[175, 176], there is no publically available sequence for the human 
homolog, and BLAST searches for human genes result in no homology.  In mice there are no 
other genes with significant homology to Erdr1, and there are no conserved domains in its 
sequence, hampering hypothesis generation regarding its biochemical mechanisms of action.  
Its chromosomal location in mice is also not definitively known, although there is some 
evidence placing it on the distal end of the X chromosome[193]. 
 There is also some discrepancy in the transcript sequence.  Erdr1 was first isolated 
from a WEHI-3B cDNA library expressed in COS-1 cells, and screened for the ability to 
induce hemoglobin synthesis.  In one clone with this activity, a 534 bp open reading frame 
(ORF) was identified.  Using this sequence as a probe, a larger sequence was identified, 
which was then used to study Erdr1 RNA species by Northern blot.  Multiple bands were 
found which, when sequenced, had a highly variable region of repetitive sequences upstream 
from the originally identified start site and a short 5’ consensus region.  None contained 
ORFs.  However, when that consensus sequence was used as a forward primer for RT-PCR 
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of WEHI-3B and mouse spleen cDNA, a transcript was amplified that contained an ORF 
with the same stop site as the 534 bp ORF, but with a start site in the 5’ consensus sequence 
(AJ539223).  In this larger ORF (630 bp) the variable region was absent, suggesting that it 
was an intron.  The 630 bp ORF was also identified in cDNA from human PBMCs, and was 
reported to have an identical sequence.[175] 
 We created a clone of Erdr1 from PMCs for the generation of protein and for 
mutational analysis of function and protein-protein interactions,.  While Dormer et al. did 
report expression in humans, we wanted to confirm this finding, given the absence of the 
sequence in the human public databases and the improbability of 100% identity between 
human and mouse sequences.  Here we show expression of Erdr1 in multiple mouse and 
human cell types, describe the methods by which Erdr1 was cloned from PMCs, analyze 
mouse transcripts by rapid amplification of cDNA ends (RACE), and provide evidence for 
expression of this ORF by a human cell line and primary human cells.   
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III. Results and Discussion 
 
Cloning of Mouse Erdr1 
 We first determined Erdr1 expression using a primer pair specific for a 150 bp 
segment near the 3’ end of the gene.  These primers have been used to validate differential 
expression on a microarray with semi-quantitative RT-PCR, and were later used for real time 
RT-PCR (see Chapter 2).  This segment of Erdr1 cDNA was easily detectible in mouse 
PMCs, murine embryonic fibroblasts (MEFs), WEHI-3B cells, as well as B16-F10 melanoma 
cells (Fig. 3.1A).  The last of these is particularly interesting given our data that stromal 
Erdr1 expression promotes metastasis.  We had found no difference in the ability of Erdr1 
knockdown cells to promote B16-F10 proliferation in vitro (not shown), and this may be 
partly due to expression by the tumor cells themselves.   
 We cloned Erdr1 from PMC cDNA to determine the transcript relevant to our 
metastasis findings.  Initially, we did not detect any PCR product using a forward primer 
beginning at the start site of the 534 bp ORF.  When the forward primer used by Dormer et 
al., in the 5’ consensus region, was substituted, we detected multiple products of differing 
lengths (Fig. 3.1B).  When these were sequenced, multiple gaps were noted compared to the 
published sequences and no ORFs were present.  A number of modifications were initially 
made to optimize the PCR conditions that were not successful, including changing the 
concentration of Mg
+2
, and the PCR reaction conditions.   
 The high GC content of the gene (68.4%) and a region near the 3’ end with a high 
potential for forming duplexes likely contributed to the difficulties encountered with RT-
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PCR analysis.   A possible problem with such a sequence is the generation of RNA or cDNA 
secondary structures that would hamper reverse transcription, primer annealing, or 
elongation.  Thus, we used a high temperature reverse transcriptase with activity at 55
o
C, in 
order denature RNA structures.   Additionally we used a specialized Taq polymerase system 
designed to reduce the strength of the hydrogen bonding in G-C rich areas and optimized the 
annealing temperature, elongation time, and the concentration of primers and Mg
+2
.    This 
approach yielded Erdr1 PCR products (Fig. 3.1C) and when these were cloned and 
sequenced, we found a 534 bp ORF sequence that was similar to the original sequence of 
Erdr1 obtained from WEHI-3B cells by Dormer et al.  This sequence is provided in Chapter 
2.   
RACE to Evaluate Start and Stop Sites in Erdr1 
 As indicated the 534 bp sequence had an ORF that corresponded to the published 
sequence from the mammary tumor cell line, but was not identical to the sequence that had 
been characterized from WEHI cells.  A more definitive method to evaluate the 5’ and 3’ 
start and stop sites in genes is RACE-PCR.  For 5’ RACE, the 5’ methylguanosine caps of 
processed transcripts are replaced with an adapter sequence, and two rounds of nested PCR 
are performed using gene specific and adapter specific primers.  For 3’ RACE, gene specific 
primers are used in combination with poly-T primers that bind the 3’ tail.  This allows 
specific amplification of targets without prior knowledge of the entire transcript 
sequence.[216]  We used two different pairs of reverse primers for 5’ RACE, and two 
different pairs of forward primers for 3’ RACE, as shown in Fig. 3.2A.  The first round of 
replication yielded 3’ RACE products of the expected sizes (Fig. 3.2B), indicating that the 3’ 
end of the PMC Erdr1 transcripts agreed with our sequence.   
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 The 5’ RACE products were varied after the first round, which might be due to non-
specific primer binding.  The second round of nested PCR also yielded multiple products for 
the 5’ RACE, none of which were the expected length (Fig. 3.2C).  Even more bands were 
detected when this was repeated.  They were identical between 4 replicate reactions, though 
some differences were seen between samples 1 and 2, which were separately ligated to the 5’ 
adapter (Fig. 3.2D).  The specificity of these reactions did not improve with differing 
annealing temperatures or Mg
2+
 concentrations (not shown).  These products were pooled 
and the largest band (~350 bp) was cloned and sequenced. 
 As shown in Fig. 3.3, there were multiple different sequences, all of which aligned 
with Erdr1 at the 3’ end, but had varying homology toward the 5’ end.  The 5’ region of 
homology shared by every clone represents the 5’ adapter sequence, and is thus an artifact.  
From the sequence alignment, these appear to result from truncations in the expected Erdr1 
sequence, perhaps from targeted RNA degradation, or shear stress on 3 dimensional RNA 
structure.  We do not think this a consequence of the quality of the RNA, since the 3’ RACE 
for Erdr1 and the 5’ RACE for -actin both produced products of the expected sizes.  Thus, 
we were unable to generate a 5’ RACE product that contained the putative start site in Erdr1.   
 This result appears to be specific to the 5’ end of Erdr1, confirming the RNA 
variability described by Dormer et al.  They did not find Erdr1 transcripts with ORFs by 
Northern blot, indicating an abundance of pre-spliced or partially degraded Erdr1 mRNA.  
The 5’ variability and repeated sequences could make RACE PCR amplification of this 
region difficult.  Furthermore, if Erdr1 transcripts are not fully processed until translation is 
required, as proposed by Dormer et al., there may be few at any given time with 5’ 
methylguanosine caps, which are added to mature transcripts.[217]  Thus, the adapter 
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sequence used for 5’ RACE might instead be ligated to the free ends of degraded transcripts, 
yielding incomplete sequences after PCR. 
 These factors could explain why databases derived from high throughput sequencing 
projects contain very few Erdr1 related sequences in the mouse, and none in the human.  
Indeed, we initially had difficulty amplifying the full-length gene with fidelity before 
optimizing both the reverse transcription and PCR reaction conditions.  Therefore, 
approaches specifically designed to detect Erdr1 sequences might be more successful than 
high throughput methods.   
 
Cloning of Human Erdr1  
 We next designed a protocol to determine the sequence of human Erdr1.  The 150 bp 
segment of Erdr1 was also present in human PBMC-derived fibrocytes (Fig. 3.4A) as well as 
PBMCs from healthy donors and CLL patients (Fig. 3.4B).  The identification of Erdr1 
expression in human fibrocytes suggests that its induction in fibrocytes though CCR5 
signaling may be relevant in human processes as well.  We also found Erdr1 protein 
production by Western blot.  The same antibody that binds Erdr1 in MEF lysates also binds a 
protein of the same size in lysate from the PBMCs from 1 of 2 healthy donors, as well as in a 
lysate from healthy human bone marrow (Fig. 3.4C).  Similarly, Dormer et al. also found 
variability in the expression of Erdr1 protein between the PBMCs of healthy donors.[175]   
 For the PBMCs, the full length Erdr1 ORF was also identified (Fig. 3.4B).  Dormer et 
al. reported an identical sequence for human and mouse Erdr1, and we also obtained an 
identical sequence (not shown) from the CLL patient PBMCs.   One obvious concern with 
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finding that the human and mouse homologs of Erdr1 were identical is that 100% 
interspecies sequence identity is uncommon.   The average sequence identity between mouse 
and human genes is 85%, with a range of 36% to 100%.[218]    The average is the same for 
amino acid and nucleotide identity, but even for highly conserved genes, 100% nucleotide 
identity is rare.  This is because mutations in the third nucleotide of each codon often have no 
effect on protein function, due to the redundancy of the genetic code.   Accordingly, a survey 
of 1196 human-mouse homologous gene pairs found 27 with identical protein sequences, but 
only 2 with identical nucleotide sequences.[218]  These 2 were not identified, but the most 
highly conserved genes tend to encode critical and structurally finely-tuned proteins, such as 
cytoskeletal, DNA-binding, or RNA-binding proteins.[218, 219]   
 Given the potential role of Erdr1 in many biological processes, and the detrimental 
effect of Erdr1 knockdown in fibroblasts, there may be considerable selective pressure 
against genetic drift in this gene.  Supporting this hypothesis is an expressed sequence tag 
(EST) isolated from the little skate (EE990695.1) with 93% sequence identity to a 3’ 272 bp 
region of mouse Erdr1.  However, due to the scarcity of genes with 100% nucleotide identity 
between mice and humans, we were concerned that the human sequence reflected 
contamination from murine cDNA.  To increase the possibility of detecting sequence 
differences, we designed 12 forward and 9 reverse primers based on the 534 bp ORF (Fig. 
3.5A, Table 3.1), which could be combined into 64 unique PCRs.  To reduce the risk of 
mouse contamination, this experiment was performed in a separate room of the Lineberger 
Comprehensive Cancer Center which has not had exposure to mice with new unopened 
reagents.  Thus, this approach greatly reduced the likelihood of failing to amplify the human 
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sequence due to lack of primer homology and significantly limited the concerns that the 
product we generated was due to contamination from murine sequences.   
 The human Burkitt’s lymphoma cell line Raji was used as a source of RNA, because 
the Burkitt’s cell line BL-70 was reported by Dormer et al. to be Erdr1+ by Western 
blot[176], and because much higher amounts of RNA could be produced from Raji cells than 
from primary human cells.  As shown in Fig. 3.5B, 36 of the 64 PCRs had products and 23 of 
those were near the predicted size (arrows).  This was highly suggestive of close homology 
between mouse and human Erdr1.  9 of these PCRs were cloned and sequenced, and 2 of 
these contained sequences identical to mouse Erdr1 (Fig. 3.6).  All other clones analyzed 
contained unrelated human genes, and none contained mouse genes.  One of the two clones 
was the full length 534 bp ORF, and the other started at position 442 (on AJ539223) and 
ended at the stop codon.  Each clone had a 1 bp difference from the mouse sequence 
conserved in the forward and reverse sequencing reactions, but these were at different 
positions, and so were attributed to sequencing or PCR error. 
 
Human nurse-like cells express an identical Erdr1 sequence to mouse cells 
 To further confirm these findings, we next sequenced Erdr1 transcripts from primary 
human cells.  Nurse-like cells (NLCs) are stromal cells that are often found in the peripheral 
blood of CLL patients, and they support the growth of CLL cells in vitro via CXCL12.[220]  
As they are circulating cells that express stromal cell markers and support tumor growth, they 
may be phenotypically related to fibrocytes.  Our data indicate that fibrocytes express Erdr1, 
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and that PBMCs from CLL patients express Erdr1 (though not more than PBMCs from 
healthy donors), so we determined if NLCs expressed Erdr1 . 
 As shown in Fig. 3.7, 3 different primer pairs led to the products of the predicted 
sizes using NLC cDNA.  Thus it is highly likely that these cells express Erdr1.  Two of these 
products that together spanned the ORF were cloned and sequenced.  As with the Raji cells, 
the consensus sequence was identical to the 534 bp ORF of mouse Erdr1 (Fig. 3.8).  Whether 
Erdr1 expression by NLCs contributes to their support of CLL cells is the subject of ongoing 
studies. 
 From these data, we conclude that mouse and human cells express Erdr1 transcripts 
containing a 534 bp ORF.  It is difficult to know whether this ORF represents the final 
transcript, but forced expression of it causes rapid death in MEFs (see Chapter 2).  
Furthermore, our data support the previous report that human Erdr1 is identical to mouse 
Erdr1.   
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IV. Experimental Procedures 
 
Mice 
C57BL/6J (WT) mice were purchased from Jackson Laboratories.  All animals were 
housed in pathogen free conditions and animal experiments were conducted using protocols 
approved by the Institutional Animal Care and Use Committee of the University of North 
Carolina at Chapel Hill. 
Cells 
Isolation of pulmonary mesenchymal cells (PMCs) was performed as previously 
described[171].  In brief, single cell suspensions of pulmonary cells were formed by 
digesting PBS-perfused lungs with collagenase (Sigma) and DNAse I type II (Sigma), and 
then lysing red blood cells with ACK lysis buffer.  These suspensions were cultured for one 
hour to remove non-adherent cells.  When cells reached confluence, in 5-7 days, PMCs were 
harvested by differential trypsinization, and used for experiments or passaged further in 
culture.  In all experiments, PMCs were used within 2 passages.  Murine embryonic 
fibroblasts (MEFs) were harvested from day E 13.5 embryos as described elsewhere [213] 
and were transduced following between 2 and 5 ex vivo passages.  Raji cells were obtained 
from ATCC.  Primary human cells (PBMCs, bone marrow, fibrocytes, and nurse-like cells) 
were obtained under IRB approved protocols.  Fibrocytes and NLCs were cultured as 
previously described.[31, 220]  All cell types were cultured in DMEM, supplemented with 
10% FBS and 1% penicillin/streptomycin.  B16-F10 melanoma and A293T cells were 
purchased (American Type Culture Collection). 
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RT-PCR and Western Blots 
PMC or MEF RNA was isolated using the RNeasy Plus kit (Qiagen) and cDNA was 
reverse transcribed at 50  C using Superscript III (Invitrogen) and oligo-dT.  Remaining 
mRNA was degraded by RNAse H (Promega).  Western blots were performed on whole cell 
lysates separated by 4-12% SDS-PAGE (Invitrogen), blocked with 3% bovine serum 
albumin, and probed with the Erdr1 specific rat antibody 8A12 (Ascenion).  HRP-conjugated 
goat anti-rat IgG (18-4818-82, Ebioscience) or donkey anti-rabbit IgG (18-8816-31, 
Ebioscience) were used as secondary antibodies, and blots were developed using an ECL kit 
(Amersham).  RACE PCR was performed using the RLM-RACE kit from Amersham, 
according to the manufacturer’s instructions, using the gene specific (“gs”) primers listed in 
Table 3.1. 
Cloning and Sequencing 
 Erdr1 was amplified from PMC and MEF cDNA using Accuprime GC Rich 
Polymerase (Invitrogen), with forward and reverse primers and thermocyler conditions 
described elsewhere[175], (Chapter 2). PCR products were cloned into pCR-BluntII-TOPO 
(Invitrogen) and transformed into TOP10 cells (Invitrogen).  Kanamycin resistant clones 
were screened for inserts by EcoRI digestion (New England Biolabs) and sequenced using 
the primers provided by the manufacturer by the UNC Genome Analysis Facility.   
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V. Figures and Tables 
 
Figure 3.1  RT-PCR for Erdr1 in mouse cells.   
A. Erdr1 by RT-PCR using primers for a 150 bp segment.  1. MEF  2. PMC  3. WEHI-3B  4. 
B16-F10  5. No template control.  B. RT-PCR for full length Erdr1 based on AJ539223, 
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D
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using conventional protocol.  Expected product size: 700 b.p.  C. RT-PCR for full length 
Erdr1 based on AJ539223, using optimized protocol.  Expected product size: 700 b.p. 1. WT 
PMC  2. CCR5
-/-
 PMC  The sizes of the DNA molecular marker bands are indicated in base 
pairs.  D.  Schematic representation of AJ539223, with the two described ORFs, the 5’ 
consensus region, and the variable region indicated. 
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Figure 3.2  RACE PCR for Erdr1 shows 3’ but not 5’ RNA integrity. 
A. Primer pairs and expected sizes for RACE nested PCR.  Numbers correspond to lanes on 
the gels below.  B. Products of the first round of nested PCR.  C. 5’ RACE products of the 
second round of nested PCR.  D. Products of the second round of 5’ RACE repeated, with 4 
replicates. 
74 
 
 
 
Figure 3.3  5’ RACE sequences aligned with the Dormer et al. sequence (AJ539223) and 
the reference sequence (NM_133362) 
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Figure 3.4  Erdr1 Expression in Human Cells.   
A. Erdr1 by RT-PCR using primers for a 150 bp segment of the gene.  1-3. Human 
fibrocytes.  4. MEF  5.  PMC.  B. Erdr1 expression for human PBMCs by RT-PCR.  1,3,4. 
CLL patient.  2, 5, 6. Healthy donor.  7.  No template negative control.  C. Western blot for 
Erdr1 protein.  1. MEF  2. Human PBMC  3. Human PBMC  4. Human PBMC from CLL 
patient.   5. Human bone marrow.    
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Figure 3.5  Combinatorial primer approach to identifying human Erdr1 from Raji cells. 
A. Schematic representation of primers used.  B. RT-PCR products.  Arrow: contains 
products near the expected size.  Numbers correspond to the clones in Fig. 6. 
9
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Figure 3.6  Erdr1 sequences isolated from Raji cells. 
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Figure 3.7  RT-PCR for Erdr1 in NLC.  
Bands show PCR products using the 3 different primer sets indicated in the table.  Circled 
bands were excised, cloned into sequencing plasmids, and sequenced.  Clone numbers refer 
to the sequences in Fig. 3.8.   
 
 
 
 
cDNA NLC NLC NLC
F Primer 229 237 361
R Primer 579 762 698
Predicted Product 350 bp 525 bp 337 bp
Clones h202 h222
h206 h226
h209 h232
1018
396
506
298
79 
 
 
Figure 3.8  Erdr1 sequences isolated from NLC. 
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Primer Strand Accession 5’ Start position Primer Sequence 
Erdr1f coding AJ539223 1 GACCGTGCGGACTTAAGATGG 
erdrorf-f4 
 
coding NM_133362 229 ATGCCCACGGGACGCACGGA 
erdr226f 
 
coding NM_133362 226 GGACGGACGGACTGACTC 
edr-3gs1 coding NM_133362 476 CTGACTCCACAAGGTAGGA  
edr-3gs2 coding NM_133362 566 CAAGATGTATGTGCCACCGACCCT 
edr-3gs3 coding NM_133362 577 ACAGTGATGTCACCCACGAAAGCA 
erdr237f 
 
coding NM_133362 237 ACCCCACGAAAGCACACACGTAGAA 
erdr336f 
 
coding NM_133362 336 CACACACGGCACACAC  
erdr361f 
 
coding NM_133362 361 GCCAGGCACACGCATC  
erdr420f coding NM_133362 420 CGCGGTCAAGATGTTCACC  
erdr442f coding NM_133362 442 CGCGGTCAAGATGTATGT  
erdr551f coding NM_133362 551 CCACGAAAGCACACACGTAG  
erdr581f coding NM_133362 581 CGTGGTCAAGATGTCTCTG  
erdr619f coding NM_133362 619 GGACGGACTCCACAAGGT  
erdr657f coding NM_133362 657 CAGGATGGAGCGATTCTCAC  
erdr263r non-coding NM_133362 263 CGCAGGCTTCCTACCTTG  
edr-h2-r non-coding NM_133362 617 CGCGTGTGTCCTGTGT  
edr-5gs1 non-coding NM_133362 596 TTGACCACGGCGTCCGCTTCTA   
edr-5gs2 non-coding NM_133362 589 ACGTGTGTGCTTTCGTGGGT 
erdr307r non-coding NM_133362 307 TGCTTTCGTGGGTGACATCA 
erdr383r non-coding NM_133362 383 TCCTGCGGATGCGTGT  
erdr468r non-coding NM_133362 468 GTCGGTGGCACATACATC  
erdr579r 
 
non-coding NM_133362 579 CGTCCGCTTCTACGTGTG  
erdr605r non-coding NM_133362 605 GGATGGCAGAGACATCTTGA  
erdr698r non-coding NM_133362 698 CTGTTGGCGTGCTCCTTC  
erdr718r 
 
non-coding NM_133362 718 TTTCTGTACGCAGTCAGG  
erdrorf-r2 non-coding NM_133362 762 TTATTGAGGGGGGGCATTTCTGTA 
 
Table 3.1  Primers used for RT-PCR. 
 
 
 
  
Chapter 4 
Discussion and Future Directions 
 
I. Summary and Model 
 
 The construction and maintenance of a supportive tumor stroma is a dynamic process 
involving many factors and many different types of cells.  In the context of metastasis, a new 
tumor stroma forms quickly, requiring the influx of multiple cell types, remodeling of the 
ECM, and cell activation and proliferation.  This process can be thought of as analogous to 
wound formation.  The dependence of metastasis on host expression of IL-6[85], S100A8 
and S100A9[221], TLR2[168], CCR5[159, 170, 171] and CCL3[159] highlight the role that 
an inflammatory milieu plays in this process.   Fibrocytes and fibroblasts respond to CCR5 
ligands by migration into the metastatic lung, where they contribute to the new supportive 
tumor stroma.[159, 171]  The data presented here implicate Erdr1 in this process. 
 We provide the first data that Erdr1 expression by stromal cells has an effect in vivo.  
The association of Erdr1 with CCR5 and the reduction of stromal promotion of metastasis 
after Erdr1 knockdown also provide a mechanism for the reduced metastasis formation in 
CCR5
-/-
 mice.  Given the anti-apoptotic activity seen in MEFs and PMCs, we propose that 
these cells promote metastasis by secreting Erdr1, which acts as a cell survival factor  
supporting the formation of a supportive stroma for metastatic nodules. 
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 A role for stromal cell survival factors in promotion of tumor growth or metastasis 
has not been widely reported.  Most factors influencing stromal cells specifically induce 
cytokine secretion or differentiation to myofibroblasts.  These contribute to the formation of 
wound-like granulation tissue, which is often found surrounding tumors, as previously 
discussed.  However, normal wound granulation tissue eventually clears, and this has been 
known for many years to depend on myofibroblast apoptosis.[222]  Tumor stroma, on the 
other hand, has been referred to as a “wound that does not heal”[10] precisely because 
normal clearing does not occur.  The promotion of metastasis by stromal Erdr1, then, may 
involve the prevention of myofibroblast apoptosis. 
 Of course, our evidence suggests a role for Erdr1 early in the tissue colonization 
process, which cannot explain long term prevention of apoptosis.  PMCs injected 
intravenously do not persist in the lung after 5 days.[171]  A recent report suggests that FGF-
2, which is present in the tumor stroma and promotes fibroblast growth, can instead induce 
fibroblast apoptosis when cells are “pre-treated” with TGF-1.[223]  If the timing of this 
effect is truly important (that is, if TGF-1 after or concurrent with FGF-2 does not have this 
effect), perhaps an anti-apoptotic signal from Erdr1 early in the process prevents this switch 
from occurring. 
 Another possibility is that the anti-apoptotic effect of Erdr1 persists for a long period 
of time.  The number of apoptotic cells in our knockdown cultures did not increase 
appreciably until passage 2 (days 5-7) after transduction.  If turnover of Erdr1 protein is low, 
local release in lung tissue early in metastasis may prevent myofibroblast apoptosis long 
enough for tumor nodules to become established.  A third possibility is that overcoming the 
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immediate stress on stromal cells of early colonization events requires an anti-apoptotic 
signal. 
 The data also show that Erdr1 expression is linked to CCR5 signaling, particularly in 
fibrocytes.  This presents a model in which fibrocytes, migrating into the inflammatory 
milieu of the new tumor site upregulate Erdr1 as they settle in the tumor stroma and become 
myofibroblasts.  Erdr1 expression promotes their survival as well as that of the cells around 
them.  These may not necessarily only be mesenchymal cells.  The recent report by Denault 
et al. linking Erdr1 to HSC function raises the possibility that HSCs might partially depend 
on it to persist and promote metastasis, as has been described by Kaplan et al.[211]  
Furthermore, Kaplan et al. demonstrated that HSCs act to promote metastasis very early in 
the process, perhaps before the tumor cells leave the primary site.  Therefore an early role for 
Erdr1 would be consistent with a mechanism mediated by HSCs. 
 We also show that 100-fold overexpression of Erdr1 leads to rapid cell death, which 
is consistent with the narrow range of anti-apoptotic activity reported by Dormer et al.[176]  
When Deneault et al. overexpressed Erdr1 in HSCs, it did not lead to cell death as it did for 
us in PMCs and MEFs.  Perhaps the detriment seen to cell survival at high doses varies by 
cell type.  The promoter in their expression vector was PGK, and perhaps this led to more 
physiological expression levels than the promoters we used.  Another difference between the 
expression vectors is the Erdr1 sequence used.  The sequence in our vector begins with the 5’ 
consensus sequence of mRNA species, as shown in Chapter 2.  With the extra 34 bp that we 
consistently found, this means that our expression vector included 200 bp of untranslated 
sequence 5’ to the start site.  The sequence in the vector used by Deneault et al. only includes 
the 534 bp transcript.  Further studies would be needed to determine if overexpression of a 
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transcript with the 200 bp 5’ untranslated region (UTR) specifically influences cell viability.  
However, we favor the interpretation that the vectors differed in dose effect.  Deneault et al. 
did not quantify Erdr1 expression in the transduced HSCs, precluding a direct comparison of 
doses achieved. 
The negative correlation of Erdr1 expression with differentiation found in multiple 
microarray studies does not necessarily imply that Erdr1 inhibits differentiation, but it does 
suggest the possibility that Erdr1 inhibits the differentiation of fibrocytes into fibroblasts in 
our metastasis model.   We believe this is not the case.  We did not find higher Erdr1 
expression in fibrocytes than in other PMC populations in vitro, except when stimulated by 
CCL4 (see Chapter 2).  Furthermore, knockdown of Erdr1 did not result in fewer fibrocytes.  
In fact, in some knockdown PMC or MEF cultures, the relative size of the fibrocyte 
population grew over time, which appeared to be a consequence of more apoptosis in the 
other populations (unpublished observations).  This phenomenon was not seen in every Erdr1 
knockdown culture, but it does emphasize that differentiation is probably not a mechanism to 
explain our results, and if it were, it would seem that Erdr1 promotes, rather than inhibits, 
fibrocyte differentiation to fibroblasts. 
 Our data also extend previous findings on the expression of Erdr1, particularly 
expression in stromal and human cells.  It appears unlikely that PMCs or MEFs express the 
630 bp ORF characterized by Dormer et al., since every sequenced clone from these cells 
contained a 34 bp insert interrupting the reading frame of that transcript.  Furthermore, the 
sequence we have obtained produces a functional protein that reduces stromal cell survival in 
high concentrations.  We have confirmed, by cloning and sequencing Erdr1 PCR products 
with multiple different primer sets, the previous report that Erdr1 appears to be identical in 
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humans and mice.  The identification of this sequence in NLCs extends the list of cell types 
that express Erdr1 to one that is phenotypically similar to the fibrocytes in our studies, and 
that is clinically relevant. 
 
II. Future Directions and Clinical Relevance 
 
 Though few studies have focused on Erdr1, the evidence to date establishes it as an 
important subject for future study.  We and others have shown that it functions as an 
antiapoptotic survival factor, with in vivo relevance to HSC activity as well as metastasis.  
Functional genomics data also implicate Erdr1 in progenitor cell and stromal cell activity, in 
addition to development, immunity, and neuronal protection/degeneration.  We have shown it 
to be induced through CCR5, which might be mediated by CREB, and other data suggest 
positive regulation by E2F1 and negative regulation by PKB (see App II).  Given these 
clues, many important questions remain. 
 Regarding metastasis, what other cell types are influenced by stroma-derived Erdr1?  
Given the microarray data implicating Erdr1 in immune activation, it might be possible that it 
plays such a role at the tumor site.  If so, is there a requirement for cell-intrinsic expression, 
or can secreted Erdr1 mediate the effect?  To answer these questions, new tools are needed.  
Genetic models in combination with recombinant protein and a neutralizing antibody would 
help to determine the cell types requiring Erdr1 intrinsically or extrinsically.  Given the data 
that Erdr1 might be important during development, the genetic models would likely have to 
be conditional to a specific cell type or inducible in adulthood.  A CRE-loxP conditional 
knockout of Erdr1 in stromal cells using the FSP-1 promoter would be useful not only in this 
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model system, but also in fibrosis models where the CCR5-mediated induction of Erdr1 in 
fibrocytes might also be important. 
 In order to engineer a conditional knockout mouse, the genomic context of the gene 
must be verified.  While the BAC clone with the distal X chromosome sequence does give 
sufficient information to flank Erdr1 with loxP sites, this sequence has not yet been 
annotated on the mouse genome.  Confirmation of this position using some of the BAC clone 
sequence as a probe for fluorescent in situ hybridization (FISH) would be necessary, and 
screening a mouse genomic library for Erdr1 to confirm the sequence would be ideal.   
 Similar studies of the human genome would also be useful.  As mentioned previously, 
the human genome databases do not contain a sequence for Erdr1, so genomic context for 
design of a FISH probe is not available.  In 2004, there remained 357 gaps in the human 
genome, which Cole et al. estimated might contain about 2000 previously unidentified 
human genes.[224]  Gaps still exist today, as is illustrated by the recent identification of 720 
new human genomic loci, 156 of which potentially encode genes.[225]  Factors that might 
inhibit the discovery of transcripts by high throughput methods include short open reading 
frames, single exon genes, or locations within heterochromic regions (found in the distal or 
central regions of chromosomes).[224]   
 These factors apply to Erdr1, suggesting why there is a scarcity of genomic sequence.  
Furthermore, our identification of a high fidelity cDNA transcript sequence required 
significant optimization of RT-PCR protocols, suggesting that high throughput methods 
might also miss Erdr1 in cDNA libraries.   With the method we have developed, a human 
genomic library could be screened for Erdr1, thus providing the flanking sequences 
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necessary for FISH probe design and for genomic annotation.  Alternatively, probing a 
Southern blot of human genomic DNA with the ORF sequence we isolated could identify 
genomic Erdr1, provided the human sequence, like the mouse, contains no introns within the 
ORF.     
 Future studies could also identify the signaling pathways that might regulate Erdr1.  
Genetic or pharmacological inhibition of mediators downstream from CCR5 would further 
test the hypothesis that CCR5 induction of Erdr1 depends on this pathway.  Protein kinase B 
(PKB), also known as Akt, is a downstream mediator of phosphoinositol-3 kinase (PI3K) 
signaling, and has been shown to mediate the induction of antiapoptotic genes upon 
stimulation of macrophages through CCR5.[226]  However, PKB knockout MEFs have 
higher Erdr1 expression than WT MEFs (App. II, 39).[227]  This does not rule out Erdr1 
CCR5-induced upregulation through PKB or PKB, but PKB appears an unlikely 
candidate.   
 Isolation and cloning of the Erdr1 promoter into a reporter construct, with sequential 
mutation of putative transcription factor binding sites, would help to elucidate the regulation 
of Erdr1 in multiple contexts.  Based on the genomic sequence from the BAC clone RP24-
143B12, there appears to be a CREB binding site within a predicted promoter region at 
position -1050 bp relative to the start site (PROSCAN weight = 2.55, promoter score = 76.09, 
cutoff = 53.00; i.e., promoters with scores above 53 have a false positive rate of 1 in 14,000 
bp).[228]  There are other potential transcription factor binding sites in this putative promoter 
region, including EGR-1 (weight = 5.74), Sp1 (3.36), and GCF (2.28).[228]  Of these, only 
CREB has been previously linked to CCR5.[229]  Furthermore one microarray experiment 
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implicates CREB binding protein (CBP) and its associated CREB co-factor p300 in Erdr1 
regulation.[230] (App. II, 43, 45) 
 Clues on the regulation and biochemical mechanism of action of Erdr1 could also be 
revealed by identification of Erdr1 binding partners.  Since the sequence contains no 
conserved domains, this would need to be an unbiased approach.  Development of a 
neutralizing antibody would allow co-immunoprecipitation (co-IP) of Erdr1 with binding 
partners, and could then be denatured, separated by two-dimensional gel electrophoresis and 
identified by mass spectrometry.  Alternatively, a proteomics array could be implemented, 
whereby plate-bound Erdr1 is allowed to bind proteins from a cell lysate, which are then 
probed by an array of protein-specific antibodies.  A systems biology approach could also be 
employed to identify genes or proteins differentially regulated in Erdr1 knockdown cells with 
or without stimulation by recombinant Erdr1, providing information on the general 
downstream effects of Erdr1 signaling. 
 Finally, the development of small molecule inhibitors of Erdr1 would allow 
evaluation of the efficacy of Erdr1 blockade as a therapeutic modality.  The strategy of 
targeting stroma-derived factors to complement cancer therapy has begun to show some 
benefit in the clinic, particularly with the targeting of VEGF-mediated angiogenesis (for 
review, see [136]).  However, this strategy has not been as efficacious as hoped, partially due 
to compensation with other pro-angiogenic factors, such as FGF[231] and PDGF-C[141].  It 
is possible that blocking a stromal cell survival factor, such as Erdr1, might reduce such 
compensation by stromal cells, and increase the efficacy of stromal targeting.   
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 As mentioned previously, a small molecule inhibitor for CCR5 is already clinically 
available for use in HIV patients.[173]  The findings presented here strengthen previous data 
implicating CCR5 in metastasis by providing another factor downstream from CCR5 that 
assists the stromal promotion of metastasis.  According to our model, the influx of fibrocytes 
into a new metastatic site via CCR5, and the subsequent ECM modification by MMP-9 and 
stromal cell support by Erdr1 are important for successful metastatic colonization.  Blocking 
CCR5, then, could interfere with metastasis early in the process, possibly increasing disease-
free survival for patients.  Moreover, this strategy targets non-neoplastic cells that have not 
yet been influenced by the tumor microenvironment, reducing the possibility of the 
development of drug resistance. 
  
 In summary, stromal cells play an important role in the promotion of tumor growth 
and metastasis.  We have identified the involvement of a recently characterized gene, Erdr1, 
in the promotion of metastasis by stromal cells.  Our data shows that stimulation of CCR5 on 
fibrocytes induces Erdr1, which acts as an antiapoptotic survival factor to support the pro-
metastatic stroma.  We have also shown that this involves the expression of a 534 bp Erdr1 
ORF, which is conserved at the cDNA level in humans and mice.  Our data are consistent 
with other studies showing that Erdr1acts as a survival factor, and provide the first evidence 
that it promotes disease in vivo.  Given this and other potential roles, Erdr1 requires further 
investigation for the translation of these findings into clinical benefit. 
 
Appendix I 
BioGPS Expression Profile of Erdr1[177, 232] 
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Appendix II 
Summary of cDNA Microarray Data Involving Erdr1 
 
 The Gene Expression Omnibus (GEO) database was searched using the term “Erdr1.”  
Results were included in this table if the change in expression was greater than 2-fold up or 
down.  Results are loosely arranged in topic areas.  Within each table, results are ordered 
from greatest fold upregulation to greatest fold downregulation, except that results from the 
same study are grouped together.  These data provide general insights into otherwise 
unknown associations between Erdr1 and various phenomena.  However, most of these 
findings were not followed up by other methods, and so they are presented only as a general 
context for direct experimental data.  
See:  http://www.ncbi.nlm.nih.gov/geo/ 
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# GEO Data Set Cells /Tissue
Comparison                              
(Denominator)
Experimental Group                          
(Numerator)
Erdr1  Fold 
Change
Ref
1 GDS1560 Skin Wild type
Induction of conditional -catenin transgenic 
(local de-differentiation)
12.89 180
2 GDS2398 Hematopoietic cells Granulocytes Hematopoietic stem cells 9.75 178
3 GDS2398 Hematopoietic cells Granulocytes
Short term repopulating hematopoietic 
progenitors
9.49 178
4 GDS2398 Hematopoietic cells Granulocytes
Long term repopulating hematopoietic 
progenitors
4.85 178
5 GDS2718 Cultured stem cells Hematopoietic Embryonic 4.19 247
6 GDS1010 Bone marrow Main poulation
Side Population (enriched for hematopoietic 
stem cells)
3.41 179
7 GDS2103 Stomach WT + H. felis Gastrin transgenic (pro-tumorigenic) + H. felis 2.07 248
8 GDS586 C2C12 cells Proliferating C2C12 Fully differentiated myotubes (day 10) 0.47 181
9 GDS2412 C2C12 cells Regular C2C12 culture conditions Induction of myotube differentiation 0.45 182
Arrays Associating Erdr1  with Less-Differentiated Cells
# GEO Data Set Cells /Tissue
Comparison                              
(Denominator)
Experimental Group                          
(Numerator)
Erdr1  Fold 
Change
Ref
10 GDS2577 Liver
Adult liver after partial hepatectomy (10 
timepoints combined)
Fetal liver (Day 10.5 to 16.5 combined) 6.40 195
11 GDS812 Embryos 2 cell stage 8 cell stage 4.60 194
12 GDS812 Embryos Blastocyst 8 cell stage 3.16 194
13 N/A Embryos day 10.5 Male Female 2.24 193
14 N/A Embryos day 11.5 Male Female 2.09 193
15 GDS401 Testis 1 day post partum 29 days post partum
0.36        
(see chart)
233
16 GDS2704 Smooth muscle cells Wild type
CHF1/Hey2 knockout (defective vascular 
development and injury response)
0.27 234
Arrays Implicating Erdr1  in Development
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GDS401:  Testes Erdr1 Expression 
During Spermatogenesis
# GEO Data Set Cells /Tissue
Comparison                              
(Denominator)
Experimental Group                          
(Numerator)
Erdr1  Fold 
Change
Ref
17 GDS2818
Intraabdominal 
adipose tissue
Adipocyte fraction Stromovascular fraction 5.30 184
18 GDS2818
Subcutaneous 
adipose tissue
Adipocyte fraction Stromovascular fraction 4.69 184
19 GDS1492 Lung CH3/HeJ female C57/BL6 female (more susceptible to fibrosis) 2.38 235
20 GDS1492 Lung A/J female C57/BL6 female (more susceptible to fibrosis) 2.20 235
21 GDS1492 Lung CH3/HeJ male C57/BL6 male (more susceptible to fibrosis) 1.92 235
22 GDS1492 Lung A/J male C57/BL6 male (more susceptible to fibrosis) 1.82 235
23 GDS2421 MEFs Media FGF-2 40 ng/mL 2.09
24 TBD Lung WT 6 hr post tumor injection CCR5-/- (fewer metastases) 6hr 0.27 See Ch. 2
25 TBD Lung WT 24 hr post tumor injection CCR5-/- (fewer metastases) 24 hr 0.37 See Ch. 2
26 TBD Lung WT 48 hr post tumor injection CCR5-/- (fewer metastases) 48 hr 0.28 See Ch. 2
Arrays Associating Erdr1  with Stromal Cells
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[74, 108, 178-182, 184, 187, 190, 192-195, 227, 230, 233-249] 
# GEO Data Set Cells /Tissue
Comparison                              
(Denominator)
Experimental Group                          
(Numerator)
Erdr1  Fold 
Change
Ref
27 GDS728 CD8+ T cells Naive CD8+ CD44low
Memory CD8+ (tetramer+ CD8+ 80 days post 
LCMV infection)
34.79 190
28 GDS1254 Embryonic stem cells Wild type SOCS3 knockout 7.54 236
29 N/A Lung 0 hr post LPS exposure by nebulizer 6 hr post LPS exposure by nebulizer 2.70 237
30 N/A
Somatosensorial 
Cortex
WT Day 4 post brain cryolesion IL-6 knockout day 4 post brain cryolesion 2.4 - 3.6 * 187
31 N/A
Somatosensorial 
Cortex
WT Day 16 post brain cryolesion IL-6 knockout day 16 post brain cryolesion 1.8 - 3.0 * 187
32 GDS325
BM-derived 
macrophages
Wild type SOCS3 knockout 2.03 192
33
E-MEXP-284  
(ArrayExpress)
Hippocampus 170 days post mock infection
170 days post ME7 Infection (Prion model, 
period of peak neuronal loss)
2.00 108
34 GDS352
CD4-CD8- splenic 
dendritic cells
Ex vivo Cultured in vitro 1.97 238
35 GDS787 Cerebral cortex Wild Type Presenilin knockout (Alzheimer's model) 0.49 239
36 GDS2903 Tumor
TC-1 cells not passaged in vivo (immune 
susceptible)
TC-1 cells selected for immune resistence by 3 
in vivo passages
0.16 240
37 GDS432
BM-derived dendritic 
cells
Wild type CIITA knockout 0.11 241
*  Numerical values not reported; entries estimated from heat map
Arrays Involving Erdr1  and Inflammation or Immunity
# GEO Data Set Cells /Tissue
Comparison                              
(Denominator)
Experimental Group                          
(Numerator)
Erdr1  Fold 
Change
Ref
38 GDS575
Prostate epithelial 
cells
Wild type Rb knockout 3.84 245
39 GDS1784 MEFs Wild type PKBa knockout 3.42 233
40 GDS46
NIH 3T3 embryonic 
fibroblasts
-Gal expressing adenovirus E2F1 expressing adenovirus 2.78 74
41 GDS2406 Lung day E 18.5 Wild type Nmyc transgenic mouse 2.29 246
42 GDS2757
Fetal liver 
erythroblast islands 
Wild type Rb knockout 2.23 247
43 GDS2160 Fibroblasts Wild type Mutation of CH1 domains in CBP and p300 0.53 229
44 GDS2820 Skin Wild type
Cannabinoid receptors CB1 and CB2 double 
knockout
0.47 249
45 GDS2160 Fibroblasts Wild type + Hypoxia
Mutation of CH1 domains in CBP and p300 + 
Hypoxia
0.43 229
46 GDS703 Extraocular muscle Wild type
Mdx mice (model for Duchenne muscular 
dystrophy)
0.36 245
47 GDS703
Gastrocnemius / 
Soleus
Wild type
Mdx mice (model for Duchenne muscular 
dystrophy)
0.28 245
48 GDS2630 Spleen Wild type Nix knockout (unrestrained erythropoiesis) 0.05 246
Other Arrays Suggesting Regulation of Erdr1
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